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CHAPTER I 
 
BACKGROUND AND RESEARCH OBJECTIVES 
 
According to the American Cancer Society, colorectal cancer is the third most common 
type of cancer in both men and women in the United States.  It is estimated that 106,680 
cases of colon cancer and 41,930 cases of rectal cancer will occur in the United States 
during 2006.  Moreover, it is expected that in the same year this type of cancer will cause 
55,170 deaths, 10% of all cancer deaths (1).  
 
1. Molecular basis of colorectal cancer 
Colorectal cancer is caused by exposure to environmental carcinogens, by inherited 
factors and/or by gene-environment interactions.  Like in the majority of cancers, most 
cases of colorectal cancer are sporadic, and a small proportion are caused by genetic 
mutations inherited in an autosomal dominant fashion (2). 
Sporadic colorectal cancer is a pathological condition that results from the accumulation 
of multiple genetic alterations that lead to the aberrant regulation of several biochemical 
pathways in the intestinal epithelial cells.  Figure 1-1 represents the adenoma-carcinoma 
sequence of colorectal cancer, a model that describes the accrual of clonally selected 
genetic changes associated with the transformation of normal to dysplastic epithelium, 
and then to colorectal adenocarcinoma (3).  
Signaling cascades that play central roles in the processes of initiation and progression of 
this disease have been identified through analysis of both hereditary and sporadic human
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Figure 1-1.  Colorectal adenoma-carcinoma sequence. 
 
tumors.  Furthermore, their functions have been validated with in vivo as well as in vitro 
model systems.  Thus, it has been recognized that among the signaling pathways that 
drive the development and progression of colorectal cancer are the Wnt/β-catenin, 
MAPK/ERK, PIK3/AKT, and TGF-β pathways. 
 
1.1. The Wnt/β-catenin signaling pathway 
The canonical Wnt/β-catenin signaling pathway, a highly conserved pathway between 
insects and vertebrates, is implicated in the control of several cellular processes in 
developing embryos as well as in adult organisms.  As depicted in figure 1-2, in non-
stimulated cells, cytoplasmic β-catenin is destabilized by a multiprotein complex formed 
by Casein Kinase 1α (CK1α), Axin, Glycogen Synthase Kinase-3β (GSK-3β), and 
Adenomatous Polyposis Coli (APC).  β-catenin bound to this complex is sequentially 
phosphorylated by CK1α and GSK-3β and, as a result, it is targeted for ubiquitin-
mediated proteasomal degradation.  Conversely, when secreted ligands of the Wnt family 
stimulate their cognate membrane receptors, which are encoded by the Frizzled genes, 
cytoplasmic Dishevelled induces Axin phosphorylation and degradation.  As a 
consequence, β-catenin phosphorylation is prevented and this allows it to translocate into 
the cell nucleus.  Nuclear β-catenin then acts as a co-activator of the T-Cell Factor 
(TCF)/Lymphoid Enhancer Factor (LEF) family of transcription factors, which induce 
transcription of a variety of target genes such as CCND1 and CMYC that promote cell 
proliferation (reviewed in (4)). 
It has been shown that the adenoma-carcinoma sequence that takes place in most cases of 
sporadic colorectal cancer is initiated by deregulation of the Wnt/β-catenin signaling 
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A B
Figure 1-2.  The Wnt/β-catenin pathway 
 
A In unstimulated cells, β-catenin (β) is associated with E-cadherin (E-cad) and with 
α-catenin (α), thus linking the cell membrane to the actin cytoskeleton.  Free β-
catenin is associated with a complex consisting of CKI, APC, Axin and GSK-3β.  
Following the priming phosphorylation by CKI, β-catenin is phosphorylated by 
GSK-3β.  Subsequently, it binds to β-TRCP, an E3 ligase, that transfers ubiquitin 
to β-catenin and marks it for proteasomal-mediated degradation. 
 
B Binding of Wnt ligands to a Frizzled (Frz) receptor results in phosphorylation of 
Dishevelled (Dsh) which causes the disruption of the Axin-dependent complex.  β-
catenin can then be translocated into the nucleus where it functions as a co-
activator of Tcf transcription factors.  c-myc, Cyclin D1, and Matrilysin are some 
of β-catenin target genes.  Soluble Frizzled-related proteins (sFRP) bind to Wnt 
ligands and inhibit Wnt pathway activation.  
 
Adapted from Kolligs F et al., 2002 (5)
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pathway (6).  Truncating and missense mutations targeting the APC gene are found in the 
early stages of about 85% of all sporadic intestinal tumors, and similar alterations are also 
the cause of Familial Adenomatous Polyposis or FAP, a hereditary condition 
characterized by the formation of hundreds to thousands of colorectal adenomas 
beginning in late childhood (2).  APC, a protein of ~312kDa with several domains, is 
involved in multiple cellular functions.  Two attributes of APC that make it important for 
colorectal tumorigenesis are its ability to interact with the microtubules during 
chromosome segregation in mitosis, and also, its role in the negative regulation of the 
Wnt/β-catenin cascade (4).  As described above, nuclear β-catenin functions as co-
activator of the TCF/LEF family of transcription factors, which induce transcription of 
genes involved in cell proliferation.  Remarkably, it has been shown that sporadic 
intestinal tumors that lack mutations in can APC carry activating mutations in CTNNB1 
(7). 
Several genetically engineered mouse models of intestinal tumorigenesis have 
corroborated the relevance of the Wnt/β-catenin pathway in this process.  The ApcMin/+ 
mouse, the first genetic model of gastrointestinal neoplasia to be generated, harbors a 
nonsense mutation in codon 850 that results in a truncated protein (8).  At an age of four 
months, the animals develop an average of thirty adenomas in the small intestine and five 
in the colon.  The tumor burden in these animals is so high that their lifespan is very short 
and, probably because of that, most tumors only reach the stage of adenoma.  Two 
additional models based on Apc mutations are the ApcΔ716/+ (9) and the Apc1638N/+ (10, 
11).  The ApcΔ716/+ mouse develops ten times more tumors than the ApcMin/+ animals of a 
similar age; nevertheless, the distribution of the adenomas is very similar and most 
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neoplasms arise in the small intestine.  Conversely, Apc1638N/wt mice have a life span of 
sixteen months and develop an average of four tumors at approximately one year of age.  
Carcinomas are observed more frequently in these animals than in the other two models, 
and liver metastases have also been reported (10).  In addition, these animals also show 
some of the extracolonic manifestations observed in FAP, i.e. desmoid tumors of the 
abdominal cavity and cutaneous cysts (12).  Animal models of intestinal cancer based on 
the disruption of β-catenin function have also been generated.  One model based on the 
expression of a constitutively active mutant of β-catenin showed that deregulation of the 
Wnt/β-catenin pathway through this approach results in the disruption of the tissue 
architecture in the intestine (13).  Also, mutant mice expressing stable β-catenin in the 
intestine, Catnb+/lox(ex3);Krt1-19+/cre and Catnb+/lox(ex3);Tg.Fabplcre, develop multiple 
intestinal neoplasms that are reminiscent of the phenotype of the ApcΔ716/+ mouse (14). 
Taken together, the findings derived from the analysis of human tumors and from animal 
models emphasize the crucial role that the Wnt/β-catenin pathway plays in the 
maintenance of homeostasis in the intestinal epithelium and the significance of its 
disruption in intestinal carcinogenesis.   
  
1.2. The Ras signaling pathway 
The Ras signaling cascade, a central regulator of eukaryotic cell proliferation, is normally 
activated in response to extracellular stimuli like growth factors and hormones.  There are 
three mammalian isoforms of RAS, Kirsten-RAS (KRAS), Harvey-RAS (HRAS), and 
Neuroblastoma-RAS (NRAS).  The biological activity of RAS, a 21KDa protein with 
intrinsic GTP-ase activity, is tightly modulated by its interaction with GTP-ase Activating 
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Proteins (GAPs) and Guanine nucleotide Exchange Factors (GEFs), which strictly control 
the cycle between the GTP- and GDP-bound states of RAS.  Mutations that affect RAS 
amino acids 12, 13 and 61 impair its ability to interact with GAPs, and lock RAS in a 
GTP-bound or active state that result in abnormal stimulation of RAS effectors.  Among 
the downstream targets of RAS activity are the RAF/MEK/ERK1/2, the RalGDS/RAL, 
and the PIK3/AKT signaling cascades, which are implicated in the regulation of cell 
proliferation, actin cytoskeleton remodeling, and survival, respectively (reviewed in 
(15)). 
The Ras signaling pathway is aberrantly activated in approximately 30% of all types of 
cancers due to genetic changes affecting the activity of several components of the 
cascade, particularly that of RAS itself (15).  Accordingly, the RAS genes are the most 
frequently mutated oncogenes in all human malignancies.  KRAS in particular is altered in 
approximately 90% of the cases of pancreatic cancer, in 35% of non-small-cell lung 
cancer, and in 50% of the cases of colorectal cancer.  Additionally, it has been reported 
that about 15% of colorectal cancer cases contain mutations in BRAF (15, 16).     
Sophisticated murine models in which constitutively active mutants of Kras are targeted 
to specific adult tissues have demonstrated that deregulation of this pathway drives 
cellular transformation and tumor formation.  In the context of intestinal cancer, studies 
by Tuveson and co-workers showed that in vivo expression of the oncogenic mutant 
KrasG12D in colonic epithelial cells causes hyperplasia and dysplasia (17).  Moreover, 
Janssen and collaborators reported that expression of human KrasG12V in the epithelium 
of both small and large intestines results in the formation of Aberrant Crypt Foci (ACF) 
in the colon, and in the development of invasive adenocarcinomas in the small intestine.  
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The results of this study also suggest that in this particular model oncogenic activation of 
KRAS may cooperate with TP53 abrogation, rather than with Wnt/β-catenin activation, 
in order to promote tumor progression (18).  Interestingly, the same group recently 
demonstrated that compound transgenic Apc1638N/wt ; KrasV12G mice have a ten-fold 
increase in tumor multiplicity and accelerated tumor progression compared to control 
animals (19).  These observations support the idea that deregulation of Kras can also 
cooperate with aberrantly activated Wnt/β-catenin to drive tumor progression. 
 
1.3. The PIK3/AKT signaling pathway 
The Phosphatidylinositol-3-Kinase (PIK3)/AKT pathway is an important regulator of cell 
growth, proliferation, survival and glucose metabolism.  Activation of receptor tyrosine 
kinases, like EGFR or the insulin receptor, induces the activation of PIK3. Activated 
PIK3 phosphorylates PIP2 into PIP3, which promotes the recruitment of AKT to the inner 
leaflet of the cell membrane, and induces AKT phosphorylation by Phosphoinositide-
dependent protein Kinases (PDKs).  AKT is a serine/threonine kinase that promotes cell 
survival by inactivating the pro-apoptotic proteins BAD, Caspase-9, and the Forkhead 
Box O (FOXO) transcription factors.  In addition, AKT-mediated phosphorylation causes 
the activation of survival proteins Nuclear Factor-Kappa B (NF-κB) and Mouse Double 
Minute 2 Homolog (MDM2).  AKT also induces cell proliferation and growth due to its 
regulatory function over GSK-3β and the Mammalian Target of Rapamycin (MTOR), 
respectively.  PIK3 activity is counterbalanced by the PIP3 phosphatases PTEN 
(Phosphatase-and-Tensin-Homolog) and SHIP (SH2-containing inositol phosphatase) 
(reviewed in (20)). 
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Recent comprehensive screenings have demonstrated that the catalytic subunit of PIK3, 
also known as PIK3CA, is mutated in more than 25% of cancers of colon, stomach, liver, 
and breast as well as in glioblastomas (21).  Thus, the elevated frequency of mutation 
indicates that PIK3CA is one of the most highly mutated oncogenes identified to date.  
Not surprisingly, functional analyses of the PIK3CA mutants found in human tumor 
tissues showed that the altered proteins have increased enzymatic activity, which 
facilitates tumor cell proliferation in the absence of growth factors as well as invasion 
(22).  Indeed, it has been observed that mutations in PIK3CA occur at the stage in which 
colorectal tumors become invasive (23). 
Up-regulation of the PIK3/AKT pathway in human cancers is also achieved through 
genetic alterations that impair the function of other components of the cascade such as 
PTEN (24).  Accordingly, inherited PTEN mutations cause Cowden Disease, a hereditary 
syndrome characterized by the development of hamartomatous polyps in the 
gastrointestinal tract, mucocutaneous lesions, and increased risk of developing neoplasms 
(24).  Furthermore, Pten null mice die during embryonic development, and heterozygous 
animals have an increased incidence of tumors in a variety of organs, which are 
associated with loss of heterozygosity in the Pten locus (25).  
 
1.4. The TGF-β signaling pathway 
The TGF-β superfamily comprises a large number of cytokines with fundamental roles in 
the regulation of cellular processes such as proliferation, differentiation, motility and 
programmed cell death.  Accordingly, the activities of these cytokines are essential for 
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adequate tissue homeostasis as well as organ development, and their disruption is 
implicated in numerous pathological processes (26).   
Three TGF-β isoforms have been found in mammals, TGF-β1, -β2 and -β3.  These 
cytokines signal through transmembrane receptors that have serine-threonine kinase 
activity.  The receptor complex consists of type I and type II receptors, and both are 
required for the activation of the heteromeric receptor complex upon ligand binding.  
There are three type I receptors, ALK1, ALK2 and ALK5/TGFBR1, and one type II 
TGF-β receptor, TGFBR2.  Intracellular signaling is initiated when a TGF-β dimer binds 
to a homodimer of TGFBR2, which consequently recruits a homodimer of TGFBR1, and 
form a heterotetrameric complex.  As a result, the activated TGFBR2 phosphorylates the 
type I receptor in the glycine-serine rich sequence located on the amino terminal side of 
the kinase domain.  This phosphorylation activates the kinase activity of the type I 
receptor, which then mediates the phosphorylation of downstream target proteins 
(reviewed in (27, 28)) (figure 1-3).  
A variety of different proteins binds to TGF-β and regulates its ability to interact with 
and activate the receptor complex.  The pro-region of TGF-β, the so-called Latency-
Associated Peptide or LAP, binds in a non-covalent fashion to the active ligand and 
together they form a latent complex.  This complex is only activated after interaction with 
αvβ6 integrin or after cleavage by proteases like plasmin and thrombospondin.  Also, 
proteins like decorin and α-2-macroglobulin bind to and sequester free TGF-β, and 
prevent receptor activation.  In addition, cell membrane proteins or co-receptors like 
endoglin and betaglycan, also known as TGFBR3, facilitate ligand binding to the 
TGFBR1 and TGFBR2, respectively (reviewed in (29)). 
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Figure 1-3.  The TGF-β signaling pathway. 
See text for details 
Adapted from Derynck and Zhang, 2003 (30)
 
Two members of the evolutionary conserved Smad family, Smad2 and Smad3, are 
activated via carboxy-terminal phosphorylation of the SSXS motif by the type I TGF-β 
receptor.  The interaction between the receptor complex and the receptor-activated Smads 
or R-Smads is facilitated by a membrane protein named SARA, Smad Anchor for 
Receptor Activation.  Thus, SARA tethers Smad2 to the inner leaflet of the cell 
membrane and facilitates receptor-mediated phosphorylation.  In the active state, Smad2 
and Smad3 form heterotrimeric complexes with the common mediator Smad4 or Co-
Smad.  These complexes translocate into the nucleus where they function as 
transcriptional activators or repressors of target genes.  Activated Smad3 and Smad4, but 
not Smad2, have the ability to bind CAGA sequences in the DNA, which are known as 
Smad-Binding Elements or SBE; however, the affinity of such interaction is rather low.  
Therefore, the association of the Smad complex with other transcription factors is 
required for effective DNA binding and control of gene expression.  Such interactions in 
conjunction with the cell type and cell state specify the transcriptional activation or 
repression of target genes (27, 28).  The transcriptional activity of Smads is negatively 
modulated by proteins like TGIF, c-SKI and SNO-N, which bind to the Smad complex 
and block its interaction with the transcriptional co-activators p300 and CBP (31-33).  
TGF-β signals are also negatively regulated by inhibitory Smads or I-Smads.  Hence, 
Smad7 competes with R-Smads for binding to the receptor complex, and induces the 
internalization of the receptor in caveolin-coated vesicles, which is followed by protein 
degradation through the proteasomal pathway.  Interestingly, TGF-β signaling induces 
expression of Smad7, which provides a TGF-β-induced negative feedback loop (34).  
Also, an additional mechanism implicated in the control of TGF-β signals is the 
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ubiquitin-mediated proteasomal degradation of effector Smads and receptor complex 
induced by Smad ubiquitin regulatory factor or Smurfs.  
Besides activating the Smad2/3 proteins, the receptor complex can modulate other non-
Smad signaling cascades like the PIK3/AKT, RhoA, MAPK/ERK, p38MAPK, and JNK 
pathways; however, the molecular mechanism by which these pathways are activated by 
TGF-β is not completely understood.  It has been established that in some systems the 
activation of these kinases occurs very rapidly, which indicates that such events may be 
direct and not secondary to transcriptional events.  Conversely, in other cell types and 
under given conditions such activation takes place very slowly, suggesting that these may 
be secondary effects (27).  
Epidemiological as well as mouse model data have shown that TGF-β1 has a potent 
tumor suppressor role in colorectal cancer, which is selected against in approximately 
50% of the cases through inactivating mutations of TGFBR2 (25%), SMAD4 (20%), and 
SMAD2 (<5%) (35).  Moreover, it has been shown that TGFBR2 mutations correlate with 
the progression of microsatellite unstable adenomas to cancer (36).  Additionally, it has 
been demonstrated that restoration of a functional TGFBR2 into several colon cancer cell 
lines reverses some characteristics of their transformed phenotype.  However, it has also 
been found that expression of a dominant negative TGFBR2 in a mouse colon cancer cell 
line prevents EMT, reduces its motility and its ability to form metastasis (37).  
Furthermore, some studies have indicated that patients with colon cancer with high levels 
of microsatellite instability and TGFBR2 BATRII mutations have an increased 5-year 
survival as compared to those that do not have such mutations (38, 39).   
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In contrast to the animal models based on Wnt pathway deregulation, Tgfb1 null mice 
develop both cecal and colonic carcinomas that, remarkably, do not show evidence of 
aberrant activation of the Wnt signaling pathway (40).  It has also been established that 
conditional inactivation of Tgfbr2 in the colonic epithelium promotes the development 
and progression of AOM-induced tumors (41). On the other hand, it has been shown that 
Smad3 null and Smad4 hemizygous animals develop colonic and intestinal neoplasias, 
respectively (42, 43).  In these two models there is no deregulation of the Wnt signaling 
pathway either.  Interestingly, recent studies have shown that chronic inflammation of the 
colon caused either by infection with Helicobacter pylori (44) or Helicobacter hepaticus 
(45) is necessary for Smad3 null and Tgfb1 null mice, respectively, to develop intestinal 
neoplasms.  Additionally, the generation of compound heterozygous Cis-ApcΔ716(+/-); 
Dpc4(+/-) animals, which develop large and invasive tumors not observed in the simple 
ApcΔ716(+/-) heterozygous animals, has suggested that deregulation of the Wnt and TGF-
β/BMP signaling pathways cooperate in the formation of intestinal neoplasms (46).  
Furthermore, the observation that ApcMin/+; Smad3-/- mice develop intestinal tumors with 
an earlier onset and higher tumor multiplicity as compared to ApcMin/+, Smad3+/+ or 
Smad3+/-, reinforces the idea of the cooperation between these signaling pathways during 
the progression of colon cancer (47). 
 
2. TGF-β signaling and the hallmarks of cancer  
The process of tumor development and progression has been found to be an evolutionary 
process in which normal cells gradually acquire genetic and epigenetic changes that give 
them growth advantage over intact cells.  Furthermore, if these few cells are allowed to 
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propagate uncontrolled, their genetic alterations are perpetuated in their progeny, which 
will be more susceptible to acquire more genetic changes.  Tumor cells in different 
organs and from diverse origins share some fundamental acquired capabilities that allow 
them to continuously proliferate avoiding the normal constraints their microenvironment 
and the organism impose.  Those attributes of tumor cells have been classified in terms of 
the biological processes they impact (48), and quite remarkably, TGF-β has been found 
to play important roles in most of them.  Relevant data that support the role of TGF-β in 
each one of the so-called hallmarks of cancer is presented next.  
 
2.1. Insensitivity to anti-growth signals 
TGF-β is a potent growth inhibitory cytokine that exerts this effect over normal 
epithelial, endothelial, myeloid and lymphoid cells.  The TGF-β growth inhibitory effect 
involves two distinct types of immediate gene responses.  On the one hand, TGF-β 
promotes the expression of inhibitors of cyclin-dependent kinases 4 and 6 (cdk4 and 
cdk6), which are implicated in the progression through the G1 phase of the cell cycle.  
Thus, TGF-β induces the expression of CDKN2B (p15INK4B) and CDKN1A (p21CIP1) that 
result the accumulation of the cdk substrates RB, p107 and p130, which in turn prevent 
the E2F transcription factors from inducing cell cycle progression.  On the other hand, 
TGF-β causes transcriptional repression of CMYC, gene that promotes cell cycle 
progression because it induces the expression of CCND2 (Cyclin D2), CDK4 and the 
translation initiation factors EIF4E and EIF2S1, among others (reviewed in (49)). 
Resistance to the TGF-β growth inhibitory effect is strongly correlated with the 
malignant progression of different types of neoplasms.  Insensitivity to the TGF-β anti-
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proliferative effect is commonly due to disruption of the function of the components of 
the TGF-β signaling cascade in the tumor cells (50).  TGFBR2, for instance, is frequently 
inactivated in colon and gastric cancers through mutations that affect a sequence of 10 
Adenines, the Big-Polyadenine-Tract or BAT RII, which is highly susceptible to 
mutations caused by defects in the DNA mismatch repair system.  Such mutations 
originate truncated receptors that lack the kinase domain that cannot propagate TGF-β 
signals.  However, alteration of the TGF-β signaling pathway by this mechanism is not 
usually found in other type of malignancies that also show remarkable resistance to the 
TGF-β growth inhibitory effect.  Instead, deletion or decreased expression of the TGF-β 
receptors, inactivation of SMAD4, SMAD2, or attenuation of TGF-β signals by the 
activation of oncogenes like HRAS, SKI and SNO are observed in tumors of the breast, 
pancreas, lung, and in melanomas (50, 51).   
 
2.2. Evasion of the immune system 
TGF-β is the most potent immunosuppressive factor described to date.  It plays a 
fundamental role in maintaining adequate immune responses because it modulates the 
proliferation and function of several cell types of the immune system (reviewed in (52)).  
Accordingly, Tgfb1 knock-out mice die few weeks after birth due to severe defects of the 
immune system; these animals develop multifocal infiltration of inflammatory cells in 
several organs, enlarged lymph nodes and undersized thymus (53).   
As expected, TGF-β plays an important role in the regulation of tumor-induced immune 
responses, and deregulation of the TGF-β signaling cascade in tumor or immune cells has 
major implications in tumor progression.  It has been shown that most cancer cells 
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produce higher amounts of TGF-β in comparison to their less malignant counterparts, and 
that the excess of this cytokine inhibits the immune response that tumor-specific antigens 
should normally trigger (52).  Indeed, cancer patients commonly present high levels of 
TGF-β in the plasma and are immunosuppressed (54).  In agreement with this 
observation, Leach et al. reported that blockade of the TGF-β signaling cascade in T-cells 
with antibodies for CTLA-4 increases the immune response against the tumor cells (55). 
TGF-β secreted by tumor cells impairs the immune response by preventing the 
proliferation and function of immune cells, and also by downregulating the expression of 
Major Histocompatibility Complex (MHC) molecules by the tumor cells themselves, 
which further weakens the immune response elicited by transformed cells (56).  
Moreover, it has been established that the immunogenicity of cancer cells can be 
importantly reduced by increasing their production of TGF-β1 (57).  Interestingly, recent 
evidence has emphasized the importance of the status of TGF-β signaling in the immune 
cell themselves in the context of development and progression of intestinal cancer in two 
mouse models.  Becker et al. showed that defects in the immune system of mice, caused 
by inactivation of TGF-β signaling through the expression of a dominant negative 
TGFBR2 in T-cells, increases tumor growth and multiplicity in the AOM colon cancer 
model through an Interleukin-6 or IL-6-dependent mechanism (58).  Furthermore, Kim 
and collaborators established that partial or complete disruption of Smad4 expression in 
T-cells promotes the development of gastrointestinal hyperplasia and cancer, 
respectively.  The tumors arisen in these mice are characterized by a dramatic expansion 
of the stromal compartment possibly due to the increase in the production of IL-4, -5, -6 
and -13 by T-cells (59).  These results clearly indicate that Smad-mediated signaling in 
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immune cells is implicated in the maintenance of intestinal tissue homeostasis, and that it 
can contribute importantly to the development and progression of tumors of the intestine.  
 
2.3. Sustained angiogenesis 
An essential role for TGF-β signaling in the repair and remodeling of blood vessels was 
recognized with the finding that inherited mutations in ENG (the gene for endoglin) and 
ALK-1, two endothelial-specific TGF-β receptors, result in defects in the vascular system 
that cause hereditary hemorrhagic telangiectasia (60, 61).  Furthermore, mouse models in 
which Tgfb1 (62), Tgfbr2 (63), Alk-1 (64) and Alk-5 (65) are disrupted die during 
embryonic development with severe defects in endothelial differentiation, which are 
reflected in abnormal vasculogenesis.  In addition, the absence of Eng also results in 
embryonic lethality in a mouse model because of major defects in angiogenesis (66). 
With respect to the role of TGF-β in the control of tumor angiogenesis, there is evidence 
that TGF-β can either promote or inhibit the formation of new blood vessels.  It has been 
reported that TGF-β1 significantly induces the expression of Vascular Endothelial 
Growth Factor (VEGF), an important regulator of new vessel development, in different 
types of tumor cells maintained in vitro (67); and that overexpression of TGF-β1 in a 
mouse model of head and neck cancer results in increased angiogenesis (68).  
Accordingly, blockade of TGF-β activity in a xenograft model reduces tumor size 
because of poor vascularization (69).  Interestingly, in vitro studies that replicate the 
conditions of hypoxia and high concentration of TGF-β observed in most tumors 
demonstrate that these two factors synergize to induce the expression of VEGF in cancer 
cells (70).  Therefore, these reports support a pro-angiogenic role for TGF-β signaling. 
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In marked contrast, Kim et al. showed that inhibition of TGF-β signaling in the MH129F 
mouse hepatoma cell line, which is sensitive to the TGF-β cytostatic effect, augments the 
production of VEGF, which results in a significant increase in vascularization and rapid 
progression of the tumors originated from that cell line (71).  Also, Go et al. reported that 
blockade of the TGF-β cascade in the epidermis of mice exposed to skin carcinogens 
results in accelerated tumor progression, due in part to increased angiogenesis (72).  
Thus, these data support an anti-angiogenic role for TGF-β signaling in these model 
systems.  The contrasting results of studies of this type may be due to intrinsic differences 
between the model systems used, such as alternative tumor types; but also to divergences 
in biochemical contexts, i.e. signaling pathway deregulation, in which the effects of TGF-
β signaling are evaluated. 
 
2.4. Genomic instability 
Instability of the genome facilitates the establishment of cancers by serving as a 
mechanism through which they can become hypermutable and able to tolerate the 
alteration of a variety of biochemical pathways.  TGF-β has been implicated in the 
regulation of the integrity of the genome by its role in different pathways that respond to 
genotoxic stress.  For instance, Ewan et al. provided evidence that supports the notion 
that TGF-β plays a protective role of the genome in the context of cellular stress (73).  
They found that the status of TGF-β signaling is positively correlated to the occurrence of 
p53-induced apoptosis and cell cycle arrest in mammary gland epithelium and embryonic 
tissues of whole-body irradiated mice.  In addition, it has been shown that Tgfb1 null 
keratinocytes have higher frequencies of chromosomal abnormalities when transduced 
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with oncogenic Kras (74), and increased gene amplification when treated with the drug 
N-phosphonoacetyl-L-aspartate or PALA (75) in comparison to Tgfb1 wild type cells.  
Conversely, the results from Kanamoto and collaborators implicate TGF-β signaling in 
the promotion of genomic instability through inhibition of Rad51-mediated DNA repair 
in Mv1Lu cells (76).  Also, Dubrovska et al. showed that TGF-β signals mediated by 
Smad3 suppress BRCA1-dependent DNA repair in response to mitomycin C, a DNA 
damaging agent (77).  Therefore these two studies provide evidence of a mechanism by 
which this cytokine may promote tumor progression in vivo.  In aggregate, these reports 
suggest that the effects of TGF-β on genomic instability might be modulated by other 
factors that ultimately lead to paradoxical effects. 
 
2.5. Tumor invasion and metastasis 
TGF-β is implicated in the regulation of several proteins involved in cytoskeletal 
organization, cell-cell and cell-extracellular matrix (ECM) adhesion, as well as in the 
control of the synthesis of ECM components and the enzymes that degrade them.  
Moreover, TGF-β is also involved in the regulation of several chemokines and cytokines 
that play important roles during the process of metastasis (78).  Consequently, TGF-β has 
direct influence on the ability of tumor cells to invade surrounding tissues and colonizing 
secondary sites.   
It has been established that TGF-β signaling induces a phenotypical change known as 
Epithelial-to-Mesenchymal Transition or EMT in epithelial cells of various origins 
(reviewed in (78)).  The transition is associated with downregulation of epithelial markers 
like E-Cadherin and ZO-1, upregulation of mesenchymal markers like α-smooth muscle 
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actin and vimentin, and the reorganization of the actin cytoskeleton into stress fibers (79).  
As TGF-β induces these changes in several types of tumor cells, it increases the motility 
and invasiveness of the cells both in vitro and in vivo (80).  Also, through upregulation of 
integrin α3β1, TGF-β promotes the invasiveness of cells derived from hepatocellular 
carcinoma in vitro.  Interestingly, analysis of human tumor tissue reinforces such positive 
correlation between the expression TGF-β1 and α3β1 by tumor cells with the occurrence 
of metastatic lesions (81). 
The potential that TGF-β has to enhance invasiveness of solid tumors is based on its 
effects on tumor cells and also on components of the tumor stroma.  Stromal fibroblasts 
become “activated” by cytokines like TGF-β1, Platelet-derived Growth Factor (PDGF) 
and IL-4 produced by tumor cells.  The fibroblasts then begin to express α-smooth 
muscle actin, secrete several ECM proteins as well cytokines and chemokines, and 
proliferate at higher rates (82).  These cells, known as myofibroblasts, are thought to play 
a very important role in the process of tissue invasion by the tumor cells mainly because 
of the cytokines and ECM proteins they secrete into the microenvironment (82).  It has 
been established that TGF-β-activated fibroblasts produce elevated amounts of growth 
factors like Hepatocyte Growth Factor or HGF, which in turn stimulates epithelial tumor 
cells to invade through basement membrane proteins in vitro.  Furthermore, these cells 
are exclusively found in the invasive edge of squamous cell carcinomas, which strongly 
argues in favor of their role in promoting tumor invasion (83).   
With respect to the role of TGF-β in the process of metastasis, several reports have 
shown that TGF-β promotes the formation of metastases for certain tumor types, and 
consequently, systemic blockade of the pathway prevents the formation of tumors in 
 21
secondary sites (80).  Some of the molecular mechanisms that implicate TGF-β in the 
colonization of new microenvironments have been elucidated (reviewed in (78)).  In the 
case of breast cancer, there is evidence that indicates that TGF-β produced by the bone 
matrix upregulates the production of Parathyroid-Hormone related Protein or PTHrP by 
breast tumor cells, and this promotes bone destruction and facilitates the development of 
bone metastases (84).  Furthermore, recent reports from Deckers et al. and Kang et al. 
indicate that Smad4-dependent TGF-β signals promote the production of IL-11 by breast 
cancer cells, which also facilitates the establishment of bone metastases in a mouse 
xenograft model (85, 86).  Nevertheless, Forrester et al. showed that the early loss of 
TGF-β signaling in tumor cells derived from mouse mammary gland leads to a 
substantial reduction in the number of lung metastasis observed in the transgenic mice 
(87).   
 
2.6. Limitless replicative potential 
The role of TGF-β signaling in the acquisition of indefinite replicative potential has not 
been studied in great detail.  Nevertheless, it has been demonstrated that TGF-β is 
implicated in repression of transcription of TERT, the catalytic unit of telomerase, the 
enzyme involved in the lengthening of the ends of the chromosomes.  Furthermore, TGF-
β-mediated control over TERT expression seems to be mediated by Smad3, given its 
capacity to bind the TERT promoter, and to require c-myc inhibition, since c-myc causes 
TERT upregulation (88, 89). The aberrant expression of telomerase facilitates the 
immortalization of transformed cells and contributes to the process of carcinogenesis 
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(78); therefore, the negative regulation of this enzyme by TGF-β supports another tumor 
suppressor function of this cytokine. 
 
2.7. Evasion of apoptosis  
Tissue homeostasis is the result of a precise balance between cell proliferation and cell 
death.  Maintenance of the equilibrium between these two processes is especially 
important in high-turnover tissues, such as the epithelium that lines the gastrointestinal 
tract.  Disruption of this balance is observed in pathological conditions like autoimmune 
disorders and cancer.   
TGF-β signaling induces programmed cell death to epithelial cells from liver, prostate, 
pancreas, and colon as well as to lymphocytes (78); and some of the molecular mediators 
of the TGF-β apoptotic program have been identified.  Among them, TIEG or TGF-β-
inducible early gene, a Zinc-finger transcription factor that is dramatically upregulated in 
pancreatic epithelial cells by TGF-β treatment, has been recognized as an important 
component of the cascade that mediates the apoptotic response in these cells (90).  Also, 
DAPK or death-associated protein kinase, another immediate response gene whose 
transcription is increased by TGF-β-induced Smad activity in Hep3B cells, is essential 
for the apoptotic response of this hepatoma cell line (91).  Another effector of the 
apoptotic signals of TGF-β has been described based on observations made in 
hematopoietic cells.  Hence, SHIP, an enzyme implicated in phospholipid metabolism, 
has been found to be upregulated in hematopoietic cells in response to TGF-β or activin 
treatments.  Furthermore, since SHIP functions as a negative regulator of AKT activation, 
its expression is associated with a marked decrease in cell survival (92).  Finally, ARTS 
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or Apoptosis-related protein in the TGF-β signaling pathway, a mitochondrial protein that 
translocates into the nucleus upon apoptotic stimuli, has been found to be necessary for 
transduction of the TGF-β apoptotic signals in rat prostate epithelial cells (93). 
Paradoxical to the data just presented, several reports have provided evidence of a 
protective effect of TGF-β against apoptosis triggered by different stimuli.  Huang et al., 
for instance, established that TGF-β1 blocked cell death caused by serum withdrawal in 
A549 human lung carcinoma cells (94).  Such protective effect was shown to be caused 
by TGF-β1-induced phosphorylation of c-Jun, which in turn results in decreased JNK 
activation.  Additionally, Shin et al. demonstrated that in HaCaT cells (keratinocytes) 
TGF-β1 induces AKT-dependent phosphorylation of the transcription factor FOXO3A 
(FKHRL-1). In such way, TGF-β1 prevents FOXO3A nuclear translocation, reduces its 
transcriptional activity and partially suppresses programmed cell death caused by serum 
starvation in NMuMG cells (mammary epithelial cells) (95).  Furthermore, Saile et al. 
reported that TGF-β1 causes a decrease in the expression of CD95L in activated rat 
hepatic stellate cells.  As a result of that, apoptosis caused by growth factor deprivation 
was significantly reduced in these cells(96).  Finally, Sachsenmeier et al. have showed 
that after loss of anchorage, human normal keratinocytes increase the steady states levels 
of TGF-β1 mRNA and the production of the active cytokine.  Hence, TGF-β1-treated 
cells show reduced DNA fragmentation and consequently have an increased potential to 
form colonies in soft agar (97).   
Importantly, the work from Sachsenmeier and coworkers draws attention to the role of 
TGF-β signaling in cell death induced by the lack of anchorage.  Signals transmitted to 
the cells by the extracellular matrix or adjacent cells induce the expression of genes 
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involved in cytoskeletal structure, differentiation and survival, and inadequate cell-matrix 
and/or cell-cell contacts trigger apoptosis in normal cells (98).  This form of cell death is 
known as anoikis, from the Greek for ‘homelessness’ (reviewed in (99, 100)).  To 
become resistant to anoikis is a selective advantage for tumor cells because it confers 
them the ability to survive without attachment and, consequently, it facilitates the 
colonization of secondary sites.  Indeed, tumor xenograft models have shown that some 
anoikis-resistant cancer cell lines have increased survival in blood circulation and 
increased capacity to form metastases (101, 102).   
In summary, the pluripotency and complexity of TGF-β signaling are reflected in the 
capacity of this cytokine to exert a wide variety of tumor suppressive and tumor 
promoting functions. Its capacity to arrest the proliferation of tumor cells, to induce 
apoptosis and senescence, and to prevent genomic instability seem to be the central 
activities of its tumor suppressive program.  In contrast, its ability to inhibit the 
proliferation and function of immune cells, to promote angiogenesis as well as invasion 
and metastasis, are crucial to its tumor promoting nature.  The data collected from animal 
models and human cancers suggest that the balance between the contrasting phases of 
this signaling cascade depend on the stage of the disease.  Thus, the anti-tumorigenic 
functions of TGF-β predominate during early phases of tumor development, whereas its 
pro-tumorigenic characteristics prevail in late stages, most likely because most tumor 
cells gain resistance to TGF-β-induced cell cycle arrest and apoptosis but remain 
responsive at levels that eventually promote tumor progression.  Moreover, the ultimate 
effect that TGF-β signals, or the lack of them, have over the process of tumor 
development depends on the status of other signaling pathways at any given tumor stage. 
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3. Research Objectives 
In order to better understand the effects of TGF-β signaling in the context of colon cancer 
development, our laboratory has conducted studies with colon cancer cell line systems 
and mouse models of intestinal cancer.  Studies with novel mouse models have shown 
that TGFBR2 can suppress the progression of intestinal tumors in the AOM colon cancer 
model, consistent with TGFBR2 acting as a tumor suppressor gene (41).  Nevertheless, 
tumors induced in animals through the use of chemical carcinogens are likely to carry 
multiple undefined genetic alterations that mask the relationship between tumor stage 
with the underlying mutations, as well as our ability to study the cooperation between 
TGF-β signaling inactivation and specific signaling pathways commonly deregulated in 
colon cancer.  Therefore, in order to better elucidate the role of TGF-β signaling 
deregulation in the development of intestinal neoplasia, we generated a mouse model that 
replicates two common genetic events observed in human colorectal cancer, APC 
mutation and TGFBR2 inactivation.  Previously, Takaku and collaborators crossed 
genetically engineered mice that harbor mutations that affect the Wnt and TGF-β 
pathways, and generated the Cis-ApcΔ716(+/-), Dpc4 (+/-) compound heterozygous mice.  
Their study revealed that simultaneous deregulation of these two signaling cascades 
cooperate to drive tumor progression (46).  However, disruption of the TGF-β pathway in 
that animal model was constitutive rather than restricted to the tumor epithelial cells, as it 
occurs in humans, and recent findings have clearly shown that the status of TGF-β 
signaling in immune and stromal cells is critical to the progression of cancer in mouse 
models (58, 103).  Furthermore, disruption of Smad4 function in that model system not 
only affected TGF-β but also BMP signals, which have been shown to play an important 
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role in intestinal homeostasis (104).  Thus, in order to circumvent these issues and 
generate a model that better reflects the conditions observed in human colorectal cancer, 
we mated Tgfbr2E2flx/E2flx;Villin-Cre mice with Apc1638N/wt mice, in order to characterize 
the effects of disrupting TGF-β signaling exclusively in intestinal epithelial cells in the 
context of Wnt pathway deregulation (chapter 2). 
In addition to the studies in mouse models of intestinal cancer, we also conducted a series 
of in vitro studies with the aim of evaluating cell-autonomous effects of TGF-β signaling 
in human colorectal cancer lines.  Our preliminary data indicated that, although 
exogenous TGF-β1 inhibits proliferation of the human colon cancer cell line HCT116 
plus chromosome 3, TGF-β also protects this cell line from undergoing anoikis.  This 
paradoxical observation clearly illustrates the dual character of TGF-β signaling in colon 
cancer, because it arrests the proliferation of malignant cells and at the same time 
facilitates their survival in hostile environments.  Hence, we investigated how general this 
protective effect is and also the biochemical mechanisms underlying it (chapter 3). 
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CHAPTER II 
 
INACTIVATION OF TRANSFORMING GROWTH FACTOR β RECEPTOR 
TYPE II INDUCES THE MALIGNANT TRANSFORMATION OF INTESTINAL 
NEOPLASMS INITIATED BY APC MUTATION 
 
Abstract 
The Transforming Growth Factor (TGF-β) signaling pathway is a tumor-suppressor 
pathway that is commonly inactivated in colon cancer.  TGF-β is a secreted ligand that 
mediates its effects through a transmembrane heteromeric receptor complex, which 
consists of type I (TGFBR1) and type II subunits (TGFBR2).  Approximately 25% of 
colon cancers carry TGFBR2 mutations, demonstrating that it is a common target for 
mutational inactivation in this cancer.  To assess the functional role of TGFBR2 
inactivation in the multistep progression sequence of colon cancer, we generated a mouse 
model that recapitulates two common genetic events observed in human colon cancer by 
mating Apc1638N/wt mice with mice that are null for Tgfbr2 in the intestinal epithelium, 
Villin-Cre;Tgfbr2E2flx/E2flx mice.  In this model, we observed a dramatic increase in the 
number of intestinal adenocarcinomas in the Apc1638N/wt;Villin-Cre;Tgfbr2E2flx/E2flx mice 
(referred to as Apc1638N/wt;Tgfbr2IEKO) compared to those mice with intact Tgfbr2, 
(Apc1638N/wt;Tgfbr2E2flx/E2flx).  Additionally, in vitro analyses of epithelial tumor cells 
derived from the Apc1638N/wt;Tgfbr2IEKO mice showed enhanced expression and activity of 
MMP-2 and MMP-9, as well as increased TGF-β1 secretion in the conditioned medium.  
Similarly, primary tumor tissues from the Apc1638N/wt;Tgfbr2IEKO mice also showed 
elevated amounts of TGF-β1 as well as higher MMP-2 activity in comparison to 
Apc1638N/wt;Tgfbr2E2flx/E2flx-derived tumors.  Thus, loss of TGFBR2 in intestinal epithelial 
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cells promotes the invasion and malignant transformation of tumors initiated by Apc 
mutation, providing in vivo evidence that Wnt signaling deregulation and TGF-β 
signaling inactivation cooperate to drive the initiation and progression, respectively, of 
intestinal cancers in vivo. 
 
Introduction 
The Transforming Growth Factor-β (TGF-β) superfamily of proteins is a family of 
dimeric secreted ligands that includes the TGF-βs, Bone Morphogenetic Proteins 
(BMPs), activins, and inhibin, among others. TGF-β regulates tissue homeostasis and 
development through affecting fundamental biological processes such as cell 
proliferation, differentiation, motility and programmed cell death.  TGF-β exerts its 
effects on the cells by binding to the transmembrane TGF-β type II receptor (TGFBR2), 
which causes the recruitment of the TGF-β type I receptor (TGFBR1) with subsequent 
activation of the receptor complex.  SMAD2 and SMAD3 are direct substrates of the 
activated TGF-β receptor complex, and once phosphorylated they form a heterotrimeric 
complex with the common mediator Smad, SMAD4.  This trimeric complex translocates 
into the nucleus where it functions as a member of different transcription factor 
complexes that regulate the expression of a variety of genes (27, 105).  In addition, TGF-
β receptor activation can induce a variety of non-SMAD signaling pathways including 
Phosphoinositol 3-kinase, Mitogen-Activated Protein Kinase, and RhoA (27). 
The role of TGF-β signaling in the process of tumor formation is complex and its effects 
appear to be context-dependent as they vary between tumors arising from different organs 
and between tumors in different stages of progression (105).  Components of the TGF-β 
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signaling pathway, including TGFBR2, SMAD2, and SMAD4, have been shown to be 
altered frequently in colon cancer, consistent with the idea that TGF-β signaling prevents 
tumor development, presumably through the induction of growth arrest, differentiation, 
or apoptosis (106-109).  However, evidence from in vitro tissue culture systems shows 
that, paradoxically, TGF-β signaling may be able to induce tumor progression due to its 
ability to promote Epithelial-to-Mesenchymal Transition, its capacity to inhibit cell death 
caused by growth factor deprivation, and its immunosuppressant function (37, 40, 95). 
To investigate the complex effects of TGF-β signaling deregulation in primary colon 
cancer, several genetically engineered mouse models have been generated that harbor 
alterations in components of the TGF-β signaling pathway; specifically Tgfbr2, Tgfb1, 
Smad2, Smad3, and Smad4 have been altered in vivo (reviewed in (110)).  Tgfb1-/-
;Prkdcscid/scid mice develop colonic carcinomas (40).  In addition, constitutive abrogation 
of Smad3 and Smad4 leads to the development colonic and intestinal neoplasms, 
respectively (42, 111).  Of interest, the Tgfb1-/-;Prkdcscid/scid and Smad3-/- mice require 
intestinal colonization with Helicobacter to develop colon neoplasms (44, 45).  
Furthermore, conditional inactivation of Tgfbr2 in the colonic epithelium promotes the 
development and progression of Azoxymethane-induced tumors (41).  Interestingly, 
compound heterozygous Cis-ApcΔ716 (+/-);Dpc4 (+/-) mice develop large and invasive 
tumors not seen in the ApcΔ716 (+/-) heterozygous mice; however, Smad2+/- mice do not 
develop intestinal neoplasms spontaneously and it does not appear that Smad2 
haploinsufficiency has a dramatic effect on the formation of intestinal tumors in the 
ApcΔ716 or Apc580D mice (112, 113).  These studies show that deregulation of the Wnt and 
SMAD pathways can cooperate in the development of intestinal neoplasia.  However, 
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because SMADs regulate BMP, activin, and inhibin signaling and because TGF-β 
activates non-SMAD pathways, these studies do not permit a precise assessment of the 
effect of deregulation of TGF-β-mediated signaling in intestinal cancer formation in vivo 
(46, 112, 113).  In addition, except for the Fabp4xat-132-Cre;Tgfbr2flx/flx mouse, these 
models abrogate TGF-β signaling in all cell types raising the question of whether the 
neoplasms observed in these mouse models are a consequence of direct loss of TGF-β 
signaling in the intestinal epithelial cells or a consequence of loss of TGF-β signaling in 
the immune or stromal cells (103, 114). 
With the aim of understanding the implications of TGF-β receptor inactivation in the 
intestinal epithelium in the process of tumor development, we generated a mouse model 
that replicates two common genetic events observed in human colorectal cancer, APC 
mutation and TGFBR2 inactivation.  Thus, we mated Tgfbr2E2flx/E2flx;Villin-Cre mice 
(referred to as Tgfbr2IEKO) with Apc1638N/wt mice in order to elucidate the effect of 
disrupting TGF-β signaling exclusively in intestinal epithelial cells in the context of Wnt 
pathway deregulation.  We observed that the Apc1638N;Tgfbr2IEKO mice develop intestinal 
adenocarcinomas at a substantially higher incidence than mice that carry the Apc1638N 
mutation alone.  Furthermore, potential cell autonomous and nonautonomous 
mechanisms through which the inactivation of Tgfbr2 in intestinal epithelial cells may 
promote rapid tumor progression were identified.  
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Experimental procedures 
 
Generation and characterization of Villin-Cre, Tgfbr2E2flx/E2flx, Apc1638N/wt mice 
The generation of transgenic Tgfbr2E2flx/E2flx, Villin-Cre and Apc1638N mice has been 
previously described (11, 12, 115).  The animals were mated in order to generate the 
following compound genotypes: Villin-Cre;Tgfbr2E2flx/E2flx (called Tgfbr2IEKO), 
Apc1638N/wt;Tgfbr2E2flx/E2flx, or Apc1638N/wt;Tgfbr2IEKO and were fed ad libitum with a 
standard rodent diet and water.  The mice were genotyped using PCR-based assays with 
visualization of the PCR products by UV transillumination after staining with ethidium 
bromide.  The following primer sequences were used for genotyping: Tgfbr2 primer 1: 
5’-GCAGGCATCAGGACCTCAGTTTGATCC-3’ and primer 2: 5’-
AGAGTGAAGCCGTGGTAGGTGAGCTTG-3’, which generate a 556bp amplicon 
from the wild type Tgfbr2 allele and a 711bp amplicon from the Tgfbr2E2flx allele; Villin-
Cre primer 1: 5’-GTGTGGGACAGAGAACAAACCG-3’ and primer 2: 5’-
TGCGAACCTCATCACTCGTTGC-3’, which generate a 1000bp product from Cre 
positive DNA (115); and Apc1638N primer 1: 5’-TGCCAGCACAGAATAGGCTG-3’, 
primer 2: 5’-TGGAAGGATTGGAGCTACGG-3’, primer 3: 5’-
GTTGTCATCCAGGTCTGGTG-3’ that generate a 300bp amplicon from the wild type 
Apc allele and 400bp amplicon from the Apc1638N mutant allele (10).  Animals with the 
genotypes Tgfbr2E2flx/E2flx or Tgfbr2IEKO were harvested at 3.5, 6, 10, 17 and 24 months of 
age in order to evaluate the morphology of the intestinal mucosa and the development of 
spontaneous tumors.  Similarly, mice with the genotypes Apc1638N/wt;Tgfbr2E2flx/E2flx and 
Apc1638N/wt;Tgfbr2IEKO were harvested at 9 and 12 months of age. 
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Tissue harvesting  
Two hours before sacrifice, the mice were injected intraperitoneally with 
Bromodeoxyuridine (BrdUrd, Sigma-Aldrich, St. Louis, MO) at a dose of 100mg/kg of 
weight.  Immediately after sacrifice, the small intestine and colon were dissected, flushed 
with PBS, opened flat, and assessed for macroscopically visible lesions.  Tissue samples 
were fixed in 10% neutral buffered formalin overnight at 4°C, and subjected to standard 
histological processing and H&E staining.  The histological evaluation of all lesions was 
performed by a gastrointestinal pathologist, who was unaware of the genotype of the 
mice. 
 
Immunostaining 
For BrdUrd immunostaining, tissue sections were deparaffinized, rehydrated, and 
endogenous peroxidase activity was blocked with H2O2 treatment.  Antigen unmasking 
was achieved by incubation with Target Retrieval Solution (DAKO, Carpinteria, CA) for 
20 minutes.  Non-specific binding was blocked by treating the sections with 1.5% rabbit 
normal serum for 10 minutes, and the immunostaining was performed with the rat 
monoclonal antibody anti-BrdUrd (clone BU1/75, Accurate Scientific, Westbury, NY) 
diluted 1:2000.  For β-catenin immunostaining, the sections were treated similarly; but 
the antigen was retrieved using boiling sodium citrate buffer pH 6.0 for 15 min.  A mouse 
monoclonal antibody anti-β-catenin (clone 14, BD Transduction Laboratories, San Diego, 
CA) was used in a 1:200 dilution with a DakoCytomation ARK system (DAKO).    
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Assessment of Cre-mediated recombination 
Genomic DNA was extracted from tissues and cell cultures using a standard phenol-
chloroform extraction protocol as previously described (116).  Cre-mediated 
recombination of Tgfbr2E2flx allele was assessed using a PCR-based assay that only 
generates an amplicon if the Tgfbr2E2flx allele has undergone Cre-mediated 
recombination.  The primer sequences are as follows:  primer 1: 5’-
AGGGATGAATGGGCTTGCTT-3’, and primer 2: 5’-CTCACCTCAGAGCCTGATTA-
3’.   
 
Tumor-derived cells isolation and long term culture 
Tumor cells were isolated following a modification of a protocol previously described 
(117).  In summary, pieces of the tumors of interest were rinsed several times in PBS 
with 10ug/mL gentamicin (10µg/mL), penicillin (20 units/mL), and streptomycin 
(20µg/mL) [referred to as PBS-A].  Subsequently, the samples were incubated for 20 
minutes in a 0.04% Sodium Hypochlorite Solution (Sigma-Aldrich) at room temperature 
and handled as sterile specimens afterward.  The tissues were rinsed with PBS-A and 
minced in small pieces, which were then centrifuged at 100 x g for 5 minutes in PBS-A.  
The pellet was resuspended in Liver Digest Medium (Gibco, Grand Island, NY) with the 
antibiotics above mentioned, and incubated for 90 minutes at 37°C with occasional 
shaking.  The samples were centrifuged at 100 x g for 5 minutes; the pellet resuspended 
in Liver Digest Medium with antibiotics, and then incubated overnight at 4°C.  
Subsequently, the samples were centrifuged and the pellet washed twice with tissue 
culture medium [RPMI-1640, 10% fetal bovine serum (FBS), 10ng/mL Epidermal 
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Growth Factor (EGF, Sigma-Aldrich), 1mL/L of ITS-X (Gibco-Invitrogen), 0.5μg/mL 
Fungizone (Gibco-Invitrogen), and the same antibiotics used previously (see above)].  
The cell suspension was plated in six-well plates coated with Matrigel (10µg/mL) (BD 
Biosciences, Bedford, MA).  When the cells reached confluence, they were disaggregated 
with 0.25% Trypsin/EDTA (Gibco/Invitrogen) and sub-cultured using standard 
technique.  To remove tumor-associated fibroblasts, the cultures were subjected to 
several rounds of differential trypsinization and the medium was changed to keratinocyte 
SFM supplemented with bovine pituitary extract and recombinant EGF 
(Gibco/Invitrogen) until no further fibroblasts were observed.  After cultures of epithelial 
cells demonstrated stable growth patterns, they were grown in CellBind (Corning, 
Corning, NY) culture vessels. 
 
Western blotting 
For evaluation of TGF-β-induced Smad-2 phosphorylation, tumor-derived cell cultures at 
70% confluence were treated with 10ng/mL TGF-β1 (R&D Systems, Minneapolis, MN) 
for 24 hours in keratinocyte SFM.  Protein lysates were prepared in 
radioimmunoprecipitation assay buffer supplemented with a complete protease inhibitor 
cocktail (Roche, Indianapolis, IN) and phosphatase inhibitor cocktails 1 and 2 (Sigma-
Aldrich), and then used for SDS-PAGE.  The mouse monoclonal antibodies anti-
phospho-Smad-2 (Ser465/467, Cell Signaling, cat. # 3101, Beverly, MA) and Smad-2 (Cell 
Signaling, cat. # 3102) were used for Western blot analyses. 
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Luciferase reporter assays 
To evaluate TGF-β-mediated transcription, tumor-derived cells were transiently 
transfected with the p3TP-lux or CAGA reporters (kindly provided by Joan Massague- 
Memorial Sloan-Kettering Cancer Center, New York, NY-, and Bert Vogelstein- Sidney 
Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, respectively) 
concomitantly with the pRL-TK reporter construct (Promega, Madison, WI).  
Subsequently, the cells were treated with 10ng/mL TGF-β1, and luciferase activity was 
evaluated 48 hours after transfection using the Dual Luciferase Reporter Assay System 
(Promega) with a Veritas luminometer (Turner Biosystems, Sunnyvale, CA).  Similarly, 
for the analysis of β-catenin-mediated transcription, the cells were transfected with the 
superTOPFLASH (118) and pRL-TK reporters, and examined 48 hours later with the 
Dual Luciferase System. 
 
Gelatin zymography 
The activity of matrix metalloproteases MMP-2 and MMP-9 produced by tumor-derived 
cells in vitro was assessed through gelatin zymography as previously reported (119).  
Briefly, 70% confluent cultures were switched from FBS-containing medium to 
Keratinocyte SFM, and the supernatant collected 24, 48, and 72 hours after serum 
deprivation started. The supernatants were concentrated with Microcon YM-10 
Centrifugal Devices (Millipore, Bedford, MA) and equivalent amounts of all samples 
were loaded into the gel.  To evaluate metalloprotease activity in the tumors, proteins 
were extracted from fragments of frozen tissue (30-80 mg) using lysis buffer [0.5M Tris 
pH7.5, 0.2M NaCl, 10mM CaCl2, 1% Triton X-100] supplemented with a complete 
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protease inhibitor cocktail (Roche).  The protein lysates were homogenized by sonication, 
clarified by centrifugation, and quantified with the BCA Protein Assay Kit (Pierce, 
Rockford, IL).  Fifty micrograms of protein per sample were loaded in 10% Zymogram 
Gels (BioRad, Hercules, CA) and processed as described above (119). 
 
In situ gelatin zymography 
In situ gelatin zymography was performed as previously published (120).  Briefly, OCT-
embedded tissues were sectioned (10 μm), and incubated at 37°C for 20 hours with 
reaction buffer [50 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM CaCl2, 2mM NaN3] 
containing 40 μg/mL FITC-labeled DQ-gelatin (Molecular Probes, Eugene, OR) and 0.02 
μg/mL 4’,6-diamidino-2-phenylindole.  At the end of the incubation period, the samples 
were evaluated by fluorescence microscopy without prior washes or fixation processes. 
 
Quantitative RT-PCR 
TaqMan Gene Expression Assays (Assays-on-Demand from Applied Biosystems) for 
Serpine1 or PAI-1 (Mm00435860), Tgfb1 (Mm00441724), Mmp2 (Mm00439508) and 
18s (4333760F) were used for quantitative RT-PCR.  mRNA was extracted from 70% 
confluent tumor-derived cultures that were serum deprived for 24h, or from snap-frozen 
tumor tissue samples using Trizol (Invitrogen) and following the manufacturer’s 
instructions.  cDNA was obtained through standard techniques. The assays were 
performed using an ABI 7900 Real-time PCR system and 18s values were used for 
normalization. 
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TGF-β1 ELISA 
The amount of TGF-β1 present in the conditioned media of tumor-derived epithelial cells 
was evaluated using the TGF-β1 Quantikine kit (R&D Systems).  The supernatants were 
obtained similarly to those used for gelatin zymography, after 48, 72 and 96h after serum 
removal from the medium.  Alternatively, fragments of frozen tissue (80-100 mg) were 
lysed using 20mmol/L Tris (pH 7.5), 140mmol/L NaCl, 1mmol/L EDTA (pH 8.0), 
1mmol/L EGTA pH (8.0), 1% Triton X-100, supplemented with a complete protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1 and 2 (Sigma).  These 
protein lysates were homogenized by sonication, clarified by centrifugation, and 
quantified with the BCA Protein Assay Kit (Pierce).  One hundred twenty-five 
micrograms of protein per tumor were used in the assay.  Latent TGF-β1 present in the 
samples was acid-activated before developing the ELISA assay according to the 
indications of the manufacturer.  
 
Results 
 
Villin-Cre;Tgfbr2E2flx/E2flx (Tgfbr2IEKO) mice show Tgfbr2 recombination in the intestinal 
mucosa  
 
It has been previously demonstrated that Cre expression in Villin-Cre transgenic mice 
occurs exclusively in the epithelial cells of the small intestine and colon, and that Cre-
mediated DNA recombination is continuous in the crypt-villus and longitudinal axes of 
these organs (115).  To confirm that the Tgfbr2E2flx allele was undergoing Cre-mediated 
recombination in the intestinal epithelium, genomic DNA from intestinal mucosa 
obtained through a blunt dissection was assessed using a PCR assay that specifically 
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amplifies the recombined Tgfbr2E2flx allele.  The recombined Tgfbr2E2flx allele could only 
be detected in the intestinal epithelium from the mice carrying the Villin-Cre transgene, 
providing evidence that the Tgfbr2E2flx allele is being deleted in the Tgfbr2IEKO mice 
(figure 2-1). 
 
Inactivation of Tgfbr2 in the intestinal epithelium neither increases proliferation of the 
epithelial cells nor induces the development of spontaneous tumors  
 
TGF-β has been shown to be a potent inhibitor of intestinal epithelial cell proliferation in 
vitro (121, 122).  In order to evaluate the effect of TGF-β signaling abrogation on the 
basal proliferation rate of the intestinal epithelium, BrdUrd incorporation in the intestines 
of Tgfbr2IEKO and Tgfbr2E2flx/E2flx mice was analyzed at 3.5, 6 and, 10 months of age 
(n=5-14 mice per time point).  The organs of the animals from both genotypic groups 
were grossly and histologically normal at each time point.  In addition, evaluation of the 
proliferation indices of the intestinal epithelial cells using BrdUrd incorporation by the 
intestinal mucosa revealed similar distribution of the indices in the Tgfbr2IEKO and 
Tgfbr2E2flx/E2flx mice at all the time points considered (P > 0.05 as determined by the 
Nonparametric Wilcoxon’s Rank Sum Test).   
With regard to spontaneous neoplasm formation, elderly Tgfbr2IEKO and Tgfbr2E2flx/E2flx 
mice (17 and 24 months of age) developed small duodenal adenomas.  Specifically, at 
17m of age 71% (n=10 of 14) Tgfbr2IEKO and 78% (n=7 of 9) Tgfbr2E2flx/E2flx mice 
developed duodenal adenomas.  Similarly, at 24 months of age 57% (n=8 of 14) 
Tgfbr2IEKO and 62% (n=5 of 8) Tgfbr2E2flx/E2flx animals had this type of lesion. 
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Figure 2-1.  Status of Tgfbr2 in the intestines of Villin-Cre;Tgfbr2E2flx/E2flx and 
Tgfbr2E2flx/E2flx mice.  Results of PCR-based assays showing evidence of recombination 
of the Tgfbr2E2flx allele in the intestinal epithelial layer of the Villin-Cre;Tgfbr2E2flx/E2flx 
but not in the Tgfbr2E2flx/E2flx mice. The Tgfbr2E2flx product generated from the intestinal 
mucosa of the Villin-Cre;Tgfbr2E2flx/E2flx mouse is presumably derived from contaminating 
submucosa.  The liver was used as a negative control and has no detectable recombined 
Tgfbr2E2Flx allele. 
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 Furthermore, we observed invasive intestinal adenocarcinomas in 24-month-old 
Tgfbr2IEKO and Tgfbr2E2flx/E2flx mice (n=2 of 14 and n=1 of 8, respectively).  Of note, the 
three colonic adenocarcinomas observed in the Tgfbr2IEKO animals did not show evidence 
of β-catenin nuclear localization, while the only invasive neoplasm observed in the 
Tgfbr2E2flx/E2flx mouse displayed nuclear localization of β-catenin.  Thus, our findings 
indicate that deletion of Tgfbr2 in the epithelial cells does not affect basal cell 
proliferation in the intestinal epithelium and that suppression of TGF-β signaling in 
intestinal epithelial cells alone is not sufficient to promote the formation of intestinal 
tumors.  This observation is consistent with those of previous studies of Fabp4xat-132-
Cre;Tgfbr2E2flx/E2flx mice, which lack Tgfbr2 in the colonic epithelium (41). 
 
Tgfbr2 inactivation promotes the malignant transformation of intestinal adenomas 
initiated by Apc mutation. 
 
In light of the infrequent formation of spontaneous tumors in Tgfbr2IEKO mice, we 
reasoned that Tgfbr2 inactivation may have its primary effect on tumorigenesis in the 
background of other gene mutations and deregulated signaling pathways.  Consequently, 
we evaluated the effect of Tgfbr2 inactivation in the context of mutations in Apc, the most 
common initiating genetic event observed in colon neoplasms (35).  Hence, we mated 
Tgfbr2IEKO mice with Apc1638N/wt mice, which develop 3-4 intestinal adenomas during 
their first year of life (11, 12), and evaluated the mice for tumor development at 9 and 12 
months of age (figure 2-2).  As shown in table 2-1, the total number of neoplastic lesions 
in the Apc1638N/wt;Tgfbr2IEKO and Apc1638N/wt;Tgfbr2E2flx/E2flx mice at 9 and 12 months of 
age was similar; however, the number of advanced tumors (i.e. adenomas with 
Figure 2-2.  Gross and histological features of the intestinal neoplasms initiated by the Apc1638N mutation.  Gross appearance of 
representative intestinal adenomas (A) and adenocarcinoma (D) observed in Apc1638N/wt;Tgfbr2E2flx/E2flx and Apc1638N/wt;Tgfbr2IEKO 
mice, respectively.  Photomicrographs of H&E-stained sections of a representative adenoma, 40X (B) and 100X (C), and an 
adenocarcinoma, 40X (E) and 100X (F).  Cystic structures filled with mucin (arrow) were frequently observed in the invasive 
neoplasms, as well as a dramatic desmoplastic response (asterisk) in the invasive component of such tumors (F). 
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Table 2-1.  Comparative tumor incidence in Apc1638N/wt;Tgfbr2E2flx/E2flx and 
Apc1638N/wt;Tgfbr2IEKO mice. 
 
 
Genotype 
Number 
of mice 
with 
tumors 
Average 
number 
of 
tumors 
per 
mouse 
Total 
number 
of 
adenomas
Total 
number of 
adenomas 
w/HGD*§
Total number of 
adenocarcinomas§
Total 
number 
of 
tumors 
9 months       
       
Apc1638N/wt, 
Tgfbr2E2flx/E2flx 
(n=10) 
8 2.62 21 0 0 21 
 
Apc1638N/wt, 
Tgfbr2IEKO  
(n=11) 
10 2.70 9 4 14 27 
       
12 months       
       
Apc1638N/wt, 
Tgfbr2E2flx/E2flx 
(n=12) 
12 4.92 44 11 4 59 
 
Apc1638N/wt, 
Tgfbr2IEKO  
(n=12) 
12 5.17 19 17 26 62 
       
 
* HGD=high grade dysplasia 
§ OR of developing high-grade lesions for the Apc1638N/wt, Tgfbr2IEKO mice is 10.2 
compared to Apc1638N/wt, Tgfbr2E2flx/E2flx mice (95% confidence interval 4.9-21.3) 
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high-grade dysplasia and adenocarcinomas) was significantly greater in the 
Apc1638N/wt;Tgfbr2IEKO than in the Apc1638N/wt;Tgfbr2E2flx/E2flx mice.  Accordingly, the odds 
ratio of probabilities for developing high-grade lesions for the Apc1638N/wt;Tgfbr2IEKO mice 
is 10.2 compared to Apc1638N/wt;Tgfbr2E2flx/E2flx mice (95% confidence interval 4.9-21.3, 
logistic regression with age adjusted).  The increase in the number of advanced neoplastic 
lesions in the Apc1638N/wt;Tgfbr2IEKO mice suggests that suppression of TGF-β signaling, 
in the context of Apc mutation and aberrant activation of the Wnt pathway, promotes the 
transformation of benign neoplasms into malignant neoplasms.  Our observations are 
similar to those made in the Cis-ApcΔ716 (+/-), Dpc4 (+/-) mouse model previously 
described (46).  In these mice, deregulation of both the Wnt and Smad pathways leads to 
a rapid progression of intestinal adenomas to invasive adenocarcinomas.  Further, the 
invasive lesions of both the Apc1638N/wt;Tgfbr2IEKO and Cis-ApcΔ716 (+/-), Dpc4 (+/-) 
animals show significant desmoplasia, and in neither of the two models metastatatic 
lesions are observed.  However, it is important to note that deregulation of the Smad 
pathway in the Cis-ApcΔ716 (+/-), Dpc4 (+/-) mice is constitutive, and it affects both TGF-
β and BMP signaling in several cellular compartments that clearly have an impact on 
tumor formation.  Recent studies have shown that impairment of TGF-β-Smad signaling 
in lymphocytes can affect intestinal epithelial cell neoplasm formation (58, 114).  
Therefore, the results obtained with the Apc1638N/wt;Tgfbr2IEKO  mouse model more 
specifically identify the role of TGF-β signaling deregulation in the epithelial cells during 
the process of intestinal tumor formation, which we propose is the most relevant model 
for assessing the role of TGF-β signaling deregulation in human intestinal cancer. 
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To investigate if loss of the growth inhibitory effect of TGF-β on the epithelial cells plays 
a role in the progression of the intestinal neoplasms of the Apc1638N/wt;Tgfbr2IEKO animals, 
we determined the proliferation index of representative adenomas arising in the 
Apc1638N/wt;Tgfbr2E2flx/E2flx and Apc1638N/wt;Tgfbr2IEKO mice.  Interestingly, we observed no 
difference between the proliferation indices of tumors from Apc1638N/wt;Tgfbr2IEKO and 
Apc1638N/wt;Tgfbr2E2flx/E2flx mice (data not shown, P = 0.24 as determined by the 
nonparametric Wilcoxon’s rank sum test). 
   
Effects of Tgfbr2 inactivation on production of factors implicated in tumor invasion in 
neoplasms arising in the Apc1638N/wt mice  
 
To assess the mechanism(s) affecting tumor progression that result from the cooperation 
of Apc inactivation with Tgfbr2 deletion in the tumors arising in the 
Apc1638N/wt;Tgfbr2IEKO mice, we derived cultures of epithelial cells from neoplasms of 
each genotype.  We first characterized the status of Apc and Tgfbr2 in these lines by 
assessing the cell lines for allelic imbalance of the Apc locus and for deletion of the 
Tgfbr2E2flx allele.  A tumor cell line derived from Apc1638N/wt;Tgfbr2IEKO mice, named 
AVcTT, displayed Apc loss of heterozygosity (LOH) and loss of Tgfbr2, whereas a cell 
line derived from a tumor from the Apc1638N/wt;Tgfbr2E2flx/E2flx mice, named ATT, 
displayed only Apc LOH (figure 2-3A).  Both cell lines demonstrated increased Wnt 
pathway activity by the superTOPFLASH reporter assay; however, only the tumor cell 
line from the Apc1638N/wt;Tgfbr2IEKO mice demonstrated loss of TGF-β-induced 
phosphorylation of Smad2 and TGF-β-mediated transcription (figure 2-3B-D).  As 
anticipated, the p3TP-lux luciferase reporter assay showed no basal or TGF-β inducible 
 45
  
Figure 2-3.  Status of Wnt and TGF-β signaling in tumor-derived epithelial cells.  A. 
Results of PCR-based analysis indicating Apc LOH in tumor lines derived from 
Apc1638N/wt;Tgfbr2IEKO (AVcTT) and Apc1638N/wt, Tgfbr2E2flx/E2flx (ATT) neoplasms, and 
recombination of the Tgfbr2E2flx allele in the AVcTT but not in the ATT line.  Genomic 
DNA obtained from normal intestinal tissue was used as the reference DNA in the assays.  
B. β-catenin-mediated transcription assessed with the superTOPFLASH reporter showing 
an increase in both the AVcTT and ATT tumor lines. S3T3 cells were used as negative 
control.  C. Analysis of Smad-2 phosphorylation by Western blot indicating loss of TGF-
β responsiveness in the AVcTT but not in the ATT line.  D. TGF-β-induced transcription 
evaluated with the p3TP-lux reporter indicates that TGF-β resistance can be restored in 
the AVcTT line by co-transfection with Tgfbr2. Of note, we observed similar results with 
the CAGA luciferase reporter.  The human colorectal cancer cell line FET was used as 
positive control for TGF-β-induced transcription. 
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activity in the AVcTT cell line, but p3TP-lux reporter activity could be induced by 
reconstitution of the AVcTT cell line with wild type Tgfbr2. 
We then assessed the effect of TGFBR2 inactivation on the secretion of proteins that 
promote tumor invasion.  We determined the concentration of secreted TGF-β1 in the 
conditioned media from the AVcTT cells and found it to be higher than that in media 
from the ATT cell line (figure 2-4A).  Moreover, we found that the concentration of 
TGF-β1 in tumor tissues was also higher in the tumors from the Apc1638N/wt;Tgfbr2IEKO 
mice compared to those from the Apc1638N;Tgfbr2E2flx/E2flx mice (figure 2-4B). These 
results suggest that TGF-β1 secretion is elevated in the tumors from the Apc1638N/wt; 
Tgfbr2IEKO mice and could have oncogenic effects by inducing angiogenesis, extracellular 
matrix remodeling and immune suppression.  
We also evaluated the production of the matrix metalloproteases MMP-2 and MMP-9 in 
the cell cultures derived from Apc1638N;Tgfbr2IEKO and Apc1638N;Tgfbr2E2flx/E2flx tumors.  
We observed increased Mmp2 mRNA expression and gelatinolytic activity in the AVcTT 
cell line compared to the ATT cell line, and found that this effect could be inhibited by 
reconstitution of the AVcTT line with Tgfbr2 (figure 2-5, A-B).  Assessment of these 
metalloproteases in tumor tissues showed that MMP-2 has a tendency to a higher 
enzymatic activity in the tumors derived from Apc1638N;Tgfbr2IEKO  as compared to those 
from Apc1638N;Tgfbr2E2flx/E2flx mice; however, we did not find any significant difference in 
MMP-9 activity in these samples (figure 2-5C).  We used in situ zymography to better 
identify the cell type involved in MMP production/activity in tumor tissues.  As shown in 
figure 2-6 minimal MMP activity was detected in the tumors from 
Apc1638N;Tgfbr2E2flx/E2flx mice.  Conversely, gelatinolytic activity was clearly observed in
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Figure 2-4.  Disruption of Tgfbr2 expression in intestinal epithelial cells alters TGF-
β1 balance both in vitro and in vivo.  A. The concentration of TGF-β1 in the 
conditioned media from AVcTT is greater than that from the ATT tumor line.  B. The 
amount of TGF-β1 is higher in tumors from Apc1638N/wt;Tgfbr2IEKO mice than in lesions 
from Apc1638N/wt, Tgfbr2E2flx/E2flx animals. 
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 Figure 2-5.  Effect of Tgfbr2 inactivation on the expression of proteins implicated in extracellular matrix remodeling and 
invasion.  A. MMP-2 and MMP-9 activities evaluated through zymography reveal that their enzymatic activities are higher in the 
AVcTT than in the ATT line.  The gelatinolytic activities of these metalloproteases are significantly reduced in the AVcTT line after 
stable reconstitution of Tgfbr2.  B. Quantitative RT-PCR analysis show that MMP-2 expression is higher in the AVcTT than in the 
ATT line, and that it is reduced in the AVcTT line after stable reconstitution of Tgfbr2.  C. The enzymatic activity of MMP-2 is also 
elevated in lesions arisen in Apc1638N/wt;Tgfbr2IEKO mice.  Inverted images were analyzed with Scion Image Software, and the average 
density for MMP-2 in Apc1638N/wt;Tgfbr2IEKO tissues was 1368.8±739.5; and for Apc1638N/wt, Tgfbr2E2flx/E2flx samples was 702.0±149.5.  
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Figure 2-6.  In situ gelatin zymography of representative tumors from the Apc1638N/wt;Tgfbr2IEKO and Apc1638N/wt;Tgfbr2E2flx/E2flx 
mice.  Tumors from Apc1638N/wt;Tgfbr2IEKO (n=3) show increased MMP activity than those from the Apc1638N/wt;Tgfbr2E2flx/E2flx mice 
(n=2).  Of note, sections incubated with, 10 μmmol/L 1,10-phenanthroline (a broad-spectrum MMP inhibitor) did not show any 
proteolytic activity (data not shown), strongly suggesting that MMPs are indeed responsible for the degradation of DQ-gelatin 
 
50
 
 
 
the Apc1638N;Tgfbr2IEKO mice and it was restricted to the epithelial component, thus 
confirming our observations on the in vitro models.  Of note, evaluation of Mmp2 mRNA 
expression by quantitative RT-PCR in the primary tumors from the Apc1638N/wt; 
Tgfbr2IEKO and the Apc1638N/wt; Tgfbr2E2flx/E2flx mice did not show a consistent difference 
between the two groups of mice, possibly because the heterogeneity of the tumor tissue 
compared to the cultures of epithelial cells, or because of the effect of differences in the 
proportion of stromal and epithelial cells in the tumors that were analyzed. 
 
Discussion 
Our results from the Villin-Cre;Tgfbr2E2flx/E2flx (Tgfbr2IEKO) mice demonstrate that Tgfbr2 
null intestinal epithelium in vivo is not highly susceptible to spontaneous tumor 
formation.  Nevertheless, in the context of an Apc mutation, Tgfbr2 inactivation promotes 
the progression of adenomas to adenocarcinomas.  These results are consistent with 
Tgfbr2 acting as a tumor suppressor gene in the intestines that primarily has effects on 
cells previously initiated into the polyp-carcinoma progression sequence.  Furthermore, 
and importantly, we can conclude from this mouse model that this effect is cell 
autonomous and not a consequence of impaired TGF-β signaling in T-cells or stromal 
cells, which has been shown to effect tumor formation in mouse models (103, 114).  
Interestingly, although TGF-β has been shown to have potent inhibitory effects on 
epithelial cells in vitro, we do not observe any detectable difference between the 
Tgfbr2IEKO and the Tgfbr2E2flx/E2flx mice with regard to proliferation within the small 
intestine or colon.  We also found no alterations in the histological appearance of the 
intestinal epithelium of the Tgfbr2IEKO mice, which is noteworthy because TGF-β has 
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been implicated in regulating apoptosis and differentiation as well as proliferation in the 
intestinal epithelium (108, 123, 124).  These results demonstrate that TGF-β signaling is 
dispensable for the homeostasis of the intestinal epithelium and may only be 
physiologically required under specific circumstances, such as in response to exposure to 
specific inflammatory stimuli (40, 45, 125).  The absence of an effect of TGF-β 
inactivation in the intestinal epithelium is in contrast to the result of BMP signaling 
disruption in the same tissue, which has been shown to lead to ectopic crypt formation 
and increased cell proliferation secondary to deregulated sonic hedgehog signaling (104, 
126, 127).  It is not clear whether the lack of a phenotypic effect is the consequence of 
compensation by other TGF-β ligand family members, such as activin, or whether it is 
because TGF-β signaling is not required for the in vivo regulation of intestinal epithelial 
proliferation, differentiation, and induction of programmed cell death. 
In light of the unremarkable effect of Tgfbr2 deletion on the basal status of the intestinal 
epithelium, it is perhaps not surprising that we did not observe the development of 
spontaneous intestinal neoplasms beyond those observed in the control mice.  Our 
findings provide further insight into the role of TGF-β signaling on intestinal tumor 
formation that has been derived from other mouse models with disrupted elements in the 
TGF-β signaling pathway, including the Tgfb1-/-; Prkdcscid/scid, ITF-dnRII (dominant 
negative Tgfbr2 transgene in the intestinal epithelium), and Smad3-/-, mouse models.  
None of these models show spontaneous intestinal tumor formation without the presence 
of a concurrent factor, either intestinal Helicobacter infection or azoxymethane treatment 
(40, 44, 45, 125).  Of interest, though, these models do not permit the precise assessment 
of TGF-β signaling disruption on cell autonomous events that affect intestinal tumor 
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formation either because they are constitutional knock-out models (e.g. Smad3-/- or Tgfb1-
/-;Prkdcscid/scid) or because they rely on dominant negative Tgfbr2 transgenes.  The Tgfb1-/-
; Prkdcscid/scid and Smad3-/- require Helicobacter colonization to develop tumors, and it is 
not clear whether the bacterial infection induces tumor formation through direct effects 
on the intestinal epithelium or through indirect paracrine effects mediated by 
lymphocytes that are TGF-β resistant (58).  Furthermore, effects of azoxymethane in the 
ITR-dnRII construct may result from attenuation of TGF-β signaling or blockade of BMP 
signaling rather than loss of TGF-β receptor function as occurs with the majority of 
TGFBR2 mutations in human colon cancer (128).   
Our prior assessment of the Fabp4xat-132-Cre;Tgfbr2E2flx/E2flx mouse, the only model to date 
that permits the assessment of cell autonomous effects of TGF-β signaling on intestinal 
neoplasm formation, showed that colon neoplasms would form after exposure of the mice 
to azoxymethane, which can induce neoplasms through β-catenin dependent and 
independent pathways (41, 129, 130).  Thus, to determine the effect of Tgfbr2 
inactivation in an in vivo model that recapitulates the genetic alterations observed in 
human colon cancer, we generated the Apc1638N/wt;Tgfbr2E2flx/E2flx +/- Villin-Cre mouse 
model.  Our results with this model provide compelling evidence that TGFBR2 acts to 
suppress the progression of initiated neoplasms and that inactivation of TGF-β signaling 
in the context of Apc mutations strongly promotes the malignant transformation of 
adenomas to adenocarcinomas.  Furthermore, in light of the increased formation of 
intestinal adenocarcinomas observed in the Cis-ApcΔ716(+/-), Dpc46(+/-) mice, our results 
in the Apc1638N/;Tgfbr2E2flx/E2flx +/- Villin-Cre suggest that inactivation of Smad signaling 
is a central effect of TGFBR2 inactivation (46).  
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With regard to the relevant biological consequences that contribute to colon cancer 
formation as a result of Tgfbr2 inactivation, we assessed the effects of loss of Tgfbr2 on 
TGF-β1 secretion and MMP-2 and MMP-9 activity, which are candidate mechanisms 
that could influence tumor invasion.  We assessed these mechanisms through the use of 
tumor epithelial cell line systems and primary tumors from the mice.  We characterized 
the cell lines for TGF-β responsiveness and activation of the Wnt signaling pathway to 
accurately determine the status of these pathways in relationship to the effects on TGF-β1 
secretion and MMP activity. It is of note that the cell line established from a neoplasm 
from an Apc1638N/wt;Tgfbr2flx/flx mouse (ATT) showed a modest level of p3TP-Lux 
induction with TGF-β that was substantially lower than the TGF-β responsive colon 
cancer cell line, FET.  We believe that this is secondary to saturation of the TGF-β 
receptor with autocrine TGF-β, but it is also possible that the TGF-β signaling pathway is 
attenuated in this cell line.  Our studies of the cell lines and tumor tissues demonstrate 
that loss of TGF-β signaling leads to invasive tumors and that these neoplasms exhibit 
profound desmoplasia and mucinous features.  These histological characteristics 
implicate factors that regulate extracellular matrix remodeling, and our in vitro studies 
and studies of the primary tumors have provided evidence suggesting that 
Apc1638N/wt;Tgfbr2IEKO tumors produce considerably higher levels of TGF-β1 and MMP-
2, which could account for their increased invasiveness.  Furthermore, we have also 
established that TGF-β signaling regulates MMP-2 expression at the level of mRNA 
synthesis in our in vitro models.  We have not investigated the role of loss of specific 
Smad and non-Smad TGF-β mediated signaling pathways in tumor formation in the 
Apc1638N/wt; Tgfbr2IEKO mice, but based on studies of the Cis-ApcΔ716(+/-), Dpc46(+/-) 
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mice and Smad3-/- mice, we predict that impaired Smad signaling has a prominent role in 
the genesis of these tumors (42, 46). 
In summary, we have shown in an in vivo model system that loss of Tgfbr2 in the 
intestinal epithelium contributes to intestinal cancer formation by promoting the 
progression of adenomas initiated by Apc mutations.  The results of these studies using 
the Villin-Cre;Tgfbr2E2flx/E2flx mice provide evidence from an in vivo model system that 
inactivation of TGFBR2 has a pathogenic role in the formation of human colon cancers 
by promoting the progression of colon adenomas to invasive adenocarcinomas.  These 
findings have significant implications regarding therapeutic strategies that target the 
TGF-β signaling pathway for the treatment of cancer. 
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CHAPTER III 
 
TRANSFORMING GROWTH FACTOR-β SIGNALING PROMOTES 
RESISTANCE TO ANOIKIS IN A SUBSET OF HUMAN COLORECTAL 
CANCER CELL LINES 
 
Abstract 
TGF-β is a cytokine involved in the regulation of numerous cellular responses, and it is 
now generally accepted that the TGF-β signaling pathway is implicated in both tumor 
suppressing and tumor promoting processes.  The relevant biological processes that TGF-
β can affect that influence tumor formation include, among others, proliferation, 
apoptosis, and differentiation.  Of particular importance to the invasive and metastatic 
behavior of cancer is the acquisition of resistance to anoikis, or cell death induced by 
inappropriate cell-cell or cell-extracellular matrix attachment, which allows anchorage-
independent survival and facilitates colonization of secondary sites.  In order to analyze 
the role of TGF-β signaling in regulating anoikis in colon cancer, we evaluated the effect 
of TGF-β1 on anoikis in a panel of established colorectal cancer cell lines.  TGF-β1-
treated HCT116+Chr3 and CBS showed a significant reduction of cell death upon loss of 
anchorage indicating that TGF-β protects these cell lines from anoikis.  Moreover, 
suppression of autocrine TGF-β signaling in HCT116+Chr3 inhibited this effect.  We 
also found that TGF-β induces the activation of the PIK3/AKT and MAPK/ERK 
pathways, and modulates the expression of the Bcl-2 family members Bim and Bcl-2, and 
that inhibition of the PIK3 and MAPK pathways attenuated the protective effect against 
anoikis.  Thus, TGF-β may paradoxically promote the malignant behavior of a subset of 
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TGF-β responsive colon cancer cell lines through cell autonomous mechanisms by 
blocking anoikis.  Several signaling cascades are involved in the TGF-β mediated effect 
on anoikis, and they appear to cooperate to promote cell survival after loss of anchorage. 
 
Introduction 
The Transforming Growth Factor-β (TGF-β) superfamily comprises a large number of 
cytokines that regulate tissue homeostasis and development due to their prominent roles 
in the regulation of fundamental processes such as cell proliferation, differentiation, 
motility and programmed cell death.  TGF-β has been shown to not only play a central 
role in development and normal organ function, but also to affect many pathological 
processes such as cirrhosis, fibrotic kidney disease, and tumorigenesis (reviewed in (131, 
132)). 
The role of TGF-β signaling during the process of tumor development is complex and its 
effects are context-dependent and can be paradoxical.  Results from in vitro and in vivo 
model systems as well as from epidemiological studies have made evident that the TGF-β 
signaling pathway can behave both as a tumor suppressor and as a tumor promoter 
pathway (27, 49).  The identification of inactivating mutations in components of the 
TGF-β signaling pathway including TGFBR2 and SMAD4 has provided strong evidence 
that TGF-β can act as a tumor suppressor in primary human cancer (108, 109).  Evidence 
for a tumor suppressor function of TGF-β signaling is also apparent from animal models 
that demonstrate an increased susceptibility to tumor development in mice in which the 
TGF-β signaling cascade has been inactivated or attenuated (40, 42, 43, 46, 72, 133).  
The tumor suppressor mechanisms of TGF-β include, among others, its ability to inhibit 
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cell-cycle progression as well as to induce senescence and apoptosis (131).  The tumor 
suppressor role of TGF-β is evident in cancers arising from a variety of organ systems, 
but is most obvious in tumors arising from the gastrointestinal tract, including colorectal 
cancer, gastric cancer, and pancreatic cancer (132).  The tumor promoting capability of 
this signaling pathway, on the other hand, has been demonstrated by the increase in 
invasiveness and metastatic potential of neoplasms arising in transgenic mice in which 
TGF-β1 or the TGF-β type I receptor are overexpressed or consitutively activated in 
tumor cells (49, 80, 134).  Furthermore, the concept that TGF-β signaling facilitates 
tumor progression is supported by the observation that some tumor cell lines lose their 
metastatic potential in xenograft systems upon disruption of the TGF-β signaling 
pathway (37).  It appears that TGF-β signaling may induce tumor progression due to the 
following: 1) its ability to promote Epithelial to Mesenchymal Transition (EMT) (37); 2) 
its immunosuppressant function (40), and/or 3) its ability to inhibit cell death caused by 
growth factor deprivation (95, 135).  Furthermore, epidemiologic studies of individuals 
with colorectal cancer correlating alterations in the TGF-β pathway with survival or 
response to treatment have produced conflicting results (38, 39, 136-138).  Thus, 
although TGF-β signaling pathway can inhibit tumor formation, it also appears capable 
of paradoxically promoting invasion and metastasis in established cell lines, especially in 
the context of breast cancer. 
One of the fundamental attributes of tumor cells that dictates their potential to invade 
tissue and metastasize is their resistance to apoptosis triggered by inadequate cell-cell 
and/or cell-matrix contacts (98).  This form of cell death is known as anoikis (from the 
Greek for ‘homelessness’, reviewed in (99, 100)).  To become resistant to anoikis 
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represents a selective advantage for tumor cells because it confers on them the ability to 
survive without proper attachment and, consequently, gives them the capacity to colonize 
secondary sites.  Indeed, tumor xenograft models have shown that anoikis-resistant 
cancer cell lines have increased survival in blood circulation and enhanced capacity to 
form metastases (101, 102, 139, 140).  In light of the conflicting results of the 
epidemiological studies of TGF-β signaling deregulation in colorectal cancer, which 
suggest that the role of TGF-β in colorectal cancer behavior can be paradoxical or tumor 
suppressing, and the evidence from in vitro systems demonstrating both tumor 
suppressing and tumor promoting effects of TGF-β in colorectal cancer cell lines, we 
have assessed the effect of TGF-β on the induction of anoikis, which is a behavior 
predicted to be associated with the progression of advanced colorectal cancer, in a panel 
of colon cancer cell lines that are responsive to TGF-β mediated growth inhibition 
 
Experimental Procedures 
 
Reagents  
n-Butyric Acid Sodium salt (cat# B-5887), Luminol (cat# A8511), and p-Coumaric acid 
(cat# C9008) were purchased from Sigma-Aldrich (St. Louis, MO).  The DNA 
topoisomerase I inhibitor Camptothecin (cat# 208925), the MEK1/2 inhibitor U0126 
(cat# 662005), and the PIK3 inhibitor LY294002 (cat# 440204) were obtained from 
Calbiochem (San Diego, CA).  TGF-β1 and IGF-I were purchased from R&D Systems 
(Minneapolis, MN) and Diagnostics Systems Laboratories (Webster, TX), respectively.  
The antibodies for p-AKT (Ser473) (cat# 9271), AKT (cat# 9272), p-ERK1/2 
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(Thr202/Tyr204) (cat# 9101), ERK1/2 (cat# 9102), Bcl2 (cat# 2872), Bcl-xL (cat# 2762), 
Bax (cat# 2772), and Bak (cat# 3792) were purchased from Cell Signaling (Beverly, 
MA).  The antibody for Bim (cat# 38-6500) was obtained from Zymed Laboratories 
(South San Francisco, CA).  The antibodies for actin (cat# sc-1616), goat anti-mouse 
IgG-HRP (cat# SC-2005), and goat anti-rabbit IgG-HRP (cat # SC-2004) were purchased 
from Santa Cruz Biotechnologies (Santa Cruz, CA).  
 
Cell culture  
The colon cancer cell lines HCT116, FET, Moser, GEO and CBS were generously 
provided by Michael Brattain (Roswell Park Cancer Institute, Buffalo, NY).  The 
HCT116 plus chromosome 3 cell line (designated here as HCT116+Chr3) was kindly 
provided by Richard Boland (Baylor University Medical Center, Dallas, TX) and John 
Carethers (University of California San Diego, San Diego, CA).  HCT116, 
HCT116+Chr3, HCT116+Chr3+DN2R, FET and Moser were grown in Dulbecco's 
Modified Eagle Medium (Gibco, Grand Island, NY), and CBS and GEO were maintained 
in McCoy’s 5A Medium (Sigma-Aldrich), and all were supplemented with 10% FBS 
(HyClone, Logan, UT). 
 
Generation of HCT116+Chr3+DN2R 
An isogenic cell line with suppressed TGFBR2 activity was generated by transfecting the 
HCT116+Chr3 cell line with a plasmid expressing a dominant negative TGFBR2 gene, 
pIRES-puro2-DN2R, which was constructed by cloning the DN2R transgene, provided 
by Harold Moses (Vanderbilt University Medical School, Nashville, TN) into the pIRES-
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puro2 vector (Clontech, Mountain View, CA). The transfection was performed using 
FuGene (Roche, Indianapolis, IN) following the manufacturer’s protocol.  A pool of 
clones was selected with 1.5μg/ml puromycin (Sigma-Aldrich) and used in the 
subsequent experiments. 
 
Thymidine incorporation assay 
With the aim of evaluating cell proliferation by means of DNA synthesis, subconfluent 
cells were treated with 10ng/ml TGF-β1 in serum free conditions.  46h after starting the 
treatment, the cells were pulsed with 4 μCi/ml [Methyl 3H]-Thymidine (Perkin Elmer, 
Wellesley, MA) and incubated at 37°C for 2 additional hours.  The cells were fixed with 
1ml 10% Trichloroacetic Acid for 30 minutes, after which they were solubilized with 
300μl of 0.2N NaOH.  100μl-aliquot of the cell lysates were resuspended in 4ml of 
scintillation fluid and the incorporation of the radioisotope was measured with a 
scintillation counter.  All the samples were prepared in triplicate. 
 
p3TP-lux reporter assay  
 In order to evaluate TGF-β-mediated transcription, tumor-derived cells were transiently 
transfected with the p3TP-lux reporter (kindly provided by Joan Massagué, Memorial 
Sloan-Kettering Cancer Center, New York, NY) concomitantly with the pRL-TK reporter 
construct (Promega, Madison, WI).  Subsequently, the cells were treated with 10ng/ml 
TGF-β1, and luciferase activity was evaluated 48h after transfection using the Dual 
Luciferase Reporter Assay System (Promega) with a Veritas luminometer (Turner 
Biosystems, Sunnyvale, CA). 
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Anoikis assay  
For the evaluation of cell death induced by the loss of anchorage, the cells of interest 
were first plated in regular cell culture vessels with FBS-containing medium at a 50% 
confluence.  24 hours later, when the cells were properly attached to the plastic, the 
medium was replaced with SFM and the cells were treated or not with 10ng/ml TGF-β1.  
After 48 hours, the cells were detached from the vessels and resuspended in SFM.  The 
cells were then seeded at a concentration of 1x106 cells/ml in Ultra Low Attachment 
Plates (Corning, Corning, NY), which prevent cell anchorage to the substrate, and treated 
or not with 10ng/ml TGF-β1 or any additional compounds to be tested.  After 8 hours in 
suspension, the cells were harvested and cell death was evaluated by Annexin V and 
Propidium Iodide staining (Annexin-V-FLUOS Staining Kit, Roche) following the 
manufacturer’s recommended protocol.  Alternatively, the cells were deprived of 
attachment for 24 hours and the occurrence of apoptosis was analyzed by Caspase-3 
activation through western blotting (protocol described below) or DNA fragmentation 
analysis (Cell Death Detection ELISA Kit, Roche).  For the AnnexinV-PI staining, 
particularly clumpy cells were treated with Accutase (Innovative Cell Technologies, San 
Diego, CA) to improve single cell suspension quality and facilitate flow cytometry 
performance. 
 
Western blotting  
 For evaluation of protein expression during anoikis western blotting was used.  Cells 
were maintained in suspension as described above, harvested, lysed with RIPA buffer 
supplemented with a complete protease inhibitor cocktail (Roche) and phosphatase 
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inhibitor cocktails 1 and 2 (Sigma-Aldrich), and then used for SDS-PAGE.  PVDF 
membranes (Pierce, Rockford, IL) were probed with the antibodies of interest under the 
conditions suggested by the maker of each antibody, and the reaction was detected by 
chemiluminescence. 
 
Results 
 
TGF-β responsiveness is restored in HCT116 upon chromosome 3 transfer  
The DNA mismatch repair (MMR) deficient human colon carcinoma cell line HCT116 is 
resistant to TGF-β due to biallelic mutational inactivation of TGFBR2.  An MMR 
proficient clone of HCT116 has been made through the transfer of chromosome 3 into 
this cell line, which reconstitutes not only the MMR gene MLH1 but also TGFBR2, 
permanently restoring TGF-β responsiveness in the HCT116+Chr3 cell line (141).  Our 
analysis revealed that in contrast to the parental HCT116 cells, the HCT116+Chr3 line 
shows a dramatic induction of the p3TP-lux reporter activity, and a suppression of cell 
proliferation upon TGF-β1 stimulation (figure 3-1). These results demonstrate that TGF-
β sensitivity is effectively restored in HCT116 upon chromosome 3 transfer, and 
moreover, that this new cell line is a well defined reagent to study the effects of restoring 
TGF-β signaling in resistant cells, because only one functional copy of TGFBR2 has been 
introduced and the reconstituted TGFBR2 is in its native chromatin environment.  
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Figure 3-1.  TGF-β1 induces transcriptional activity of the p3TP-lux reporter 
construct and growth arrest in HCT116+Chr3.  A. Parental cell line HCT116, as well 
as HCT116+Chr3 and HCT116+Chr3+DN2R cells were transienlty transfected with the 
p3TP-lux and pRL-TK reporter constructs, and treated with 10ng/mL TGF-β1.  B. DNA 
synthesis was evaluated in HCT116 and HCT116+Chr3 treated with 10ng/mL TGF-β1 
for 48h.  All experiments were performed in triplicates. The bars correspond to S.E. 
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TGF-β1 protects the HCT116+Chr3 cell line from anoikis  
TGF-β signaling is involved in the regulation of multiple cellular responses disrupted 
during the process of tumor formation that can affect cancer progression.  Deregulation of 
anoikis, for instance, contributes to the malignant behavior of many types of neoplastic 
cells by allowing anchorage-independent survival and facilitating colonization of 
secondary sites.  With the aim of evaluating the effect of TGF-β1 on HCT116+Chr3 
undergoing this type of cell death, the parental cell line HCT116, HCT116+Chr3, and 
HCT116+Chr3 transduced with a dominant negative mutant of TGFBR2 
(HCT116+Chr3+DN2R) were maintained under conditions of no attachment with or 
without exogenous TGF-β1.  After eight hours in suspension, early apoptotic cells were 
detected by changes in their cell membrane by Annexin-V and Propidium Iodide staining.  
Alternatively, the cells were collected after 24h and the extent of DNA fragmentation was 
determined using a Cell Death Detection ELISA assay.  As shown in figure 3-2, 
autocrine TGF-β1 protects HCT116+Chr3 from undergoing anoikis as judged by the 
lower amount of cell death observed in untreated HCT116+Chr3 as compared to that of 
HCT116+Chr3+DN2R.  In addition, the protective influence is further enhanced by the 
addition of exogenous TGF-β1.  
 
TGF-β1 protects the colorectal cancer line CBS from undergoing anoikis  
In order to determine if TGF-β also protects other TGF-β responsive colon cancer cell 
lines against anoikis, we analyzed the effect of TGF-β stimulation on a set of cell lines 
derived from human colorectal carcinomas deprived from anchorage.  Furthermore, since 
TGF-β responsiveness was reconstituted in HCT116+Chr3 by the insertion of one copy
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Figure 3-2.  TGF-β1 protects HCT116+Chr3 cells from anoikis.  The cells were 
treated with 10ng/mL TGF-β1 in serum free conditions in regular tissue culture flasks.  
After 48h, 1x106 cells/mL were placed in suspension in “Ultra Low Attachment Clusters” 
(Costar) with the same concentration of TGF-β1.  A. 8h after, early changes in the cell 
membrane organization were evaluated by Annexin V and Propidium Iodide staining 
using flow cytometry.  B. Alternatively, 24h later DNA fragmentation was assessed with 
the ELISA-based assay.  The assays were run in triplicate. The bars represent S.E. 
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of the TGFBR2 in its native chromatin environment, we chose to study the response to 
the loss of substrate in a subset of colorectal cancer cell lines naturally sensitive to TGF-β 
growth inhibition.  Thus, we evaluated the occurrence of cell death upon the loss of 
anchorage in the human colorectal cancer lines GEO, Moser, FET and CBS through 
analysis of DNA fragmentation and Caspase-3 activation.  Our analysis revealed that, 
even though TGF-β has been shown to cause growth arrest to all these cell lines, its 
effects in terms of anoikis are quite diverse.  Hence, our results show that while 
exogenous TGF-β protects CBS from undergoing anoikis, it increases the amount of cell 
death in FET lacking anchorage.  Further, we found that treatment with TGF-β does not 
have a significant effect on anoikis in GEO and Moser (figure 3-3).   
 
Smad-independent pathways are activated by exogenous TGF-β1 in HCT116+Chr3 and 
CBS that are in an anchorage free state  
 
Although TGF-β1 has been shown to induce cell death in several cell lineages, including 
some colon adenoma cell lines, there are some reports of cell lines protected by this 
cytokine from apoptosis triggered by different stimuli.  It has been established, for 
instance, that TGF-β1 blocks cell death caused by growth factor deprivation to the mouse 
mammary gland NMuMG cell line (95), to A549 human lung carcinoma cells (94), and to 
activated rat hepatic stellate cells (HSC) (96).  
The paradoxical effects of TGF-β in terms of apoptosis regulation emphasize the 
relevance of the cellular context in controlling the responses to this cytokine.  Since this 
contextual effect is likely due to differential signaling pathway alterations, we studied 
whether non-Smad signaling pathways may be modulated by TGF-β1 and involved with
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Figure 3-3.  Effect of TGF-β1 treatment on colorectal cancer cell lines deprived 
from anchorage.  The TGF-β-responsive colon cancer cell lines FET, Moser, GEO and 
CBS were treated as previously described (legend of figure 2B).  The amount of anoikis 
was assessed with the “Cell Death Assay” (Roche) after 24 hours. 
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the suppression of anoikis in HCT116+Chr3.  We evaluated the PIK3/AKT pathway, 
which has been implicated in the protective effect of TGF-β1 against apoptosis (95).  We 
observed that exogenous TGF-β1 induces AKT phosphorylation in HCT116+Chr3 kept 
in suspension (figure 3-4A).  Additionally, we found that inhibition of autocrine TGF-β 
signaling in HCT116+Chr3, by forced expression of the DN2R mutant, dramatically 
reduces the basal activity of ERK1/2 in HCT116+Chr3 (figure 3-4B).   
Next, we investigated if TGF-β-induced activation of the MAPK/ERK and PIK3/AKT 
pathways have a functional role in the protection against anoikis.  For that purpose, we 
applied the pharmacological inhibitors U0126 and LY294002 to TGF-β-treated 
HCT116+Chr3 in order to reduce the activity of MEK1/2 and PIK3, respectively, and 
evaluated the amount of anoikis under such conditions.  We found that blockade of these 
enzymes dramatically increases the amount of cell death in HCT116+Chr3 kept in 
suspension and, although the cells were more sensitive to blockade of the MAPK/ERK 
pathway alone, preventing the activity of the two pathways concurrently had an additive 
effect on the induction of anoikis (figure 3-4C).  In addition, we found that treatment of 
HCT116+Chr3+DN2R with LY294002 alone, or in combination with U0126, increased 
the amount of cell death to a greater extent than in HCT116+Chr3 (figure 3-4C).  From 
these results we infer that autocrine TGF-β signaling can partially prevent cell death after 
loss of anchorage even in the presence of MEK1/2 and PIK3 inhibitors.  Furthermore, we 
also found that the cells that were exposed to the pharmacological inhibitors and 
simultaneously treated with exogenous TGF-β1 showed a lower induction of cell death 
when compared to untreated cells or the cells that express the DN2R mutant.  Thus, these 
observations implicate other mechanisms in TGF-β-mediated resistance against cell death 
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(figure 3-4C). Taken together, our results suggest that even though the activation of the 
PIK3/AKT and MAPK/ERK pathways is necessary for TGF-β to protect HCT116+Chr3 
against anoikis, modulation of these two signaling cascades is likely not the only 
mechanism through which TGF-β exerts its protective effect. 
We next assessed the roles of MAPK/ERK and PIK3/AKT in TGF-β-mediated protection 
of CBS cells against anoikis. We observed that exogenous TGF-β treatment induces the 
phosphorylation of ERK1/2, but not of AKT.  Furthermore, with the aim of establishing 
if ERK1/2 activation in TGF-β-treated CBS cells is relevant for the protection against 
anoikis, we treated the cells with the MEK1/2 inhibitor U0126 and measured the effect 
effect of ERK1/2 inhibition on anoikis.  This analysis showed that TGF-β-induced 
activation of the MAPK/ERK pathway is necessary for increased resistance against 
anoikis, since inhibition of these enzymes partially overcomes TGF-β’s protective effect 
(figure 3-5).  
 
Activation of TGF-β signaling correlates with increase in Bcl-2 expression  
The preceding results provided evidence that MAPK/ERK1/2 and PIK3/AKT-
independent mechanisms are modulated by TGF-β signaling so that HCT116+Chr3 and 
CBS are protected from undergoing anoikis even upon blockade of these signaling 
cascades.   
The Bcl-2 family of proteins plays a fundamental role in the regulation of apoptosis, and 
several of its members have been shown to be targeted for disruption during colon cancer 
progression (142, 143).  For that reason we decided to evaluate the expression of pro- and 
anti-apoptotic members of this family of proteins in both lines while undergoing anoikis.
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Figure 3-4.  TGF-β-induced activation of the MAPK/Erk and PIK3/AKT pathways 
in HCT116+Chr3 is necessary for protection against anoikis.  A. Western blot 
analysis of phosphorylated Erk 1/2 (Thr202/Tyr204) and total ERK1/2 in cells treated 
with TGF-β1.  B. Western blot analysis of phosphorylated AKT (S473) and total AKT in 
cells treated with TGF-β1. C. Cell death analysis for HCT116+Chr3 and 
HCT116+Chr3+DN2R deprived from substrate for 24h and treated with 10mM 
LY294002, 5mM U0126 and/or 10ng/mL TGF-β1.  These results are representative of 
several assays.  Each experiment was done in triplicate. The bars indicate S.E. 
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Figure 3-5.  TGF-β-induced activation of the MAPK/Erk pathway in CBS is 
necessary for protection against anoikis.  Western blot analysis of Caspase-3, ERK1/2 
and AKT and their active forms in CBS maintained in suspension for 24 hours.  The cells 
were treated with 5uM of U0126 and/or 10ng/mL TGF-β1. 
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We observed that TGF-β treatment inhibits the expression of the pro-apoptotic protein 
Bim in HCT116+Chr3 deprived from anchorage.  Importantly, we also found that TGF-
β-induced downregulation of Bim expression is independent of the MAPK/ERK and 
PIK3/AKT pathways, because even in the presence of pharmacological inhibitors to 
MEK1/2 or PIK3, TGF-β potently inhibits the expression of Bim (figure 3-6A).  We also 
established that TGF-β stimulation of HCT116+Chr3 is associated with an increase in the 
expression of anti-apoptotic Bcl-2, possibly due in part to Bim downregulation.  Of note, 
we observed that TGF-β does not alter other Bcl-2 family members like Bcl-xL (figure 3-
6A), Bax or Bak (not shown).  In summary, these results suggest that the modulation 
exerted by TGF-β signaling upon the activity of PIK3/AKT, MAPK/ERK and members 
of the Bcl-2 family is responsible for the persistent resistance to anoikis displayed by 
HCT116+Chr3 as compared to HCT116+Chr3+DN2R.  Additionally, we also established 
that TGF-β treatment of the CBS cell line does not affect Bim expression but does cause 
an increase in the level of expression of total Bcl-2, presumably enhancing its 
antiapoptotic activity and contributing to the TGF-β-mediated protective effect (figure 3-
6B). 
 
Signaling network deregulation in FET, Moser and GEO and TGF-β’s effect in anoikis  
Our analysis of the expression of activated ERK1/2 and AKT showed that they are involved 
in TGF-β-mediated protection of HCT116+Chr3 and CBS.  Consequently, we examined 
the status of these pathways in the colorectal cell lines that are not protected from anoikis 
by TGF-β in order to determine the specificity of TGF-β induction of these pathways in 
the settings of anoikis.  This analysis revealed that TGF-β1 does not induce the activation 
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Figure 3-6.  TGF-β signaling modulates the expression of Bim and Bcl-2 in 
HCT116+Chr3, and the expression of Bcl-2 in CBS deprived from anchorage.  A. 
Western blot analysis of BimS, BimL, Bcl-2 and Bcl-xL in HCT116+Chr3 and 
HCT116+Chr3+DN2R deprived from anchorage for 24h and treated with TGF-β1, the 
pharmacological inhibitors LY294002 and U0126. B. Western blot analysis of BimS, 
BimL, Bcl-2 and Bcl-xL in CBS deprived from anchorage for 24h and treated with 
exogenous TGF-β1.  
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of ERK1/2 or AKT in Moser or GEO (figure 3-7), which is presumably associated with 
the lack of a protective effect.  Conversely, we found that although TGF-β treatment 
promotes anoikis in FET, it induces the activation of ERK1/2, but not AKT, a similar 
effect to that seen in CBS cells, which are protected from this type of cell death by TGF-
β (figure 3-7).  
Confronted with the paradoxical results obtained with FET, in which TGF-β enhances the 
occurrence of anoikis while it stimulates the activation of the MAPK/ERK signaling 
pathway as it does in cells that are protected against cell death, we hypothesized that 
critical components of the signaling network required for TGF-β to exert a protective 
effect against anoikis were absent in FET cells.  Therefore, we studied whether the 
induction of PIK3/AKT activity concomitant with TGF-β pathway stimulation would 
lead to resistance against anoikis as shown in HCT116+Chr3.  For this purpose, we first 
treated the cells with IGF-I and found that this treatment alone reduces the amount of cell 
death after loss of anchorage (figure 3-8).  Subsequently, we were able to establish that 
when applied simultaneously with IGF-I, TGF-β1 does not reduce the protective effect of 
PIK3/AKT activation induced by IGF-I, but on the contrary, it enhances the protection 
exerted by this cytokine, further protecting the cells from anoikis (figure 3-8).  Moreover, 
we found that the enhanced protective effect exerted by the combination of TGF-β and 
IGF-I requires the activation of MAPK/ERK pathway, because treatment with the 
MEK1/2 inhibitor U0126 increases the amount of cell death to the levels observed in 
untreated cells. 
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Figure 3-7.  Effect of TGF-β1 treatment on Caspase-3, ERK1/2 and AKT activation 
in colorectal cancer cell lines deprived from anchorage.  Western Blot assays for 
Caspase-3, ERK1/2 and AKT and their active forms in FET, Moser and GEO maintained 
in suspension for 24 hours with or without exogenous TGF-β1. 
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Figure 3-8.  The TGF-β, MAPK/Erk and PIK3/AKT pathways cooperate to prevent 
anoikis in FET cells.  A. FET cells were treated as described in figure 2.  100ng/mL 
IGF-I alone or in combination with 10ng/mL TGF-β were added while the cells were in 
suspension, and the amount of cell death was assessed with the ELISA-based assay after 
24h.  B. Western Blot assays for Caspase-3, AKT and ERK1/2 and their active forms in 
FET cells treated with IFG-I, U0216 and/or TGF-β1. 
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Discussion 
Survival signals are conveyed to epithelial cells upon engagement of cell surface 
receptors with the adequate components of the extracellular matrix (ECM), or receptors 
of neighboring cells (98).  Cell death triggered by the lack of appropriate cell-cell or cell-
ECM contacts, called anoikis, is postulated to be a mechanism for maintaining tissue 
architecture, and in the context of cancer progression, it represents a barrier for tumor 
invasion and metastasis (98-100).  Our studies indicate that in a subset of colorectal 
cancer cell lines, several of such survival signaling cascades, the MAPK/ERK, the 
PIK3/AKT, and the mitochondrial cell death pathways are modulated by TGF-β 
signaling, resulting in increased resistance against anoikis.  Moreover, these findings 
provide evidence that the cellular context determines the effects TGF-β exerts on 
colorectal cancer lines, and that paradoxically, it can induce cell cycle arrest and 
resistance against anoikis concurrently.  
Several reports have shown that tumor cells with an increased ability to survive in 
conditions of detachment also have an enhanced capacity to metastasize in in vivo 
systems.  Tumor cells less susceptible to anoikis due to alterations in proteins involved in 
integrin signaling (144), cell-cell adhesion (102) or the mitochondrial cell death pathway 
(145) have greater metastatic potential.  Our results suggest then that by increasing 
resistance to cell death caused by lack of or by inadequate anchorage, TGF-β signaling 
enhances the capacity of some colorectal cancer cells to invade and colonize secondary 
sites.  This finding strongly supports previous data that indicate that late-stage events in 
colorectal cancer progression can be promoted by cell-autonomous TGF-β signaling (37).   
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Our results also highlight that TGF-β’s effects on tumor progression are context-
dependent.  We were able to establish that even though TGF-β stimulation causes growth 
inhibition of HCT116+Chr3, CBS, Moser, GEO, and FET; it induces different responses 
at the level of anoikis in these colorectal cancer lines.  It is very likely that the diversity in 
the responses is due to the different oncogenic backgrounds of these cell lines even 
though they were all derived from human colorectal cancers.  Accordingly, we 
established that TGF-β inhibits cell death upon detachment in HCT116+Chr3 and CBS, 
and that in HCT116+Chr3 this protective effect is associated with the activation of the 
MAPK/ERK and the PIK3/AKT pathways, as well as with the modulation of expression 
of pro-apoptotic Bim and anti-apoptotic Bcl-2.  In contrast, the protective effect in CBS is 
associated only with TGF-β-induced activation of MAPK/ERK and the upregulation of 
Bcl-2 expression.  Also, we found that exogenous TGF-β does not have an effect on the 
occurrence of anoikis in Moser or GEO cells, which we predict is related to the inability 
of TGF-β to modulate the activity of the MAPK/ERK or PIK3/AKT pathways in these 
cell lines.  Finally, we were able to determine that in the background of exogenous 
activation of PIK3/AKT, TGF-β promotes resistance against anoikis in FET cells, and 
that activation of the MAPK/ERK pathway was required for this protective effect. 
A number of reports have shown that TGF-β signaling exerts a protective effect against 
apoptosis triggered by different stimuli in various cell systems, and that diverse 
molecular mechanisms mediate the resistance against cell death in these different cell 
lines.  Thus, TGF-β protects microglia cells from FasL-induced death by a mechanism 
dependent on the activity of MEK (146).  In contrast, neuronal cells are protected from 
apoptosis caused by Ca2+ overloading or growth factor deprivation by TGF-β-induced 
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upregulation of Bcl-2 expression (135).  Furthermore, TGF-β prevents cell death upon 
growth factor withdrawal to mammary epithelial cells in an AKT-dependent fashion (95).  
We now provide evidence of the molecular mechanisms through which TGF-β protects 
human colorectal cancer lines against cell death caused by the lack of anchorage. 
The relevance of the MAPK/ERK and PIK3/AKT cascades in protection against anoikis 
has been described in a wide variety of model systems.  It has been reported that 
oncogenic forms of RAS (147), RAF and AKT (148, 149) promote resistance against 
anoikis in epithelial cells, and it has become clear that the contribution of each one of 
these pathways to the protective effect depends on the cell type.  Furthermore, it has been 
reported that TGF-β signaling interacts with these two survival pathways, both in Smad-
dependent and Smad-independent manners, and in concert, they modulate several cell 
responses of tumor cells to diverse apoptotic stimuli (reviewed in (150)).   
The results of our studies also implicate the regulation of the Bcl-2 family of proteins in 
TGF-β-mediated protection against anoikis.  We found that the pro-apoptotic BH3-only 
protein Bim, and its downstream target, the pro-survival protein Bcl-2 are modulated by 
TGF-β in HCT116+Chr3 deprived from anchorage.  Bim is an important regulator of 
apoptosis in epithelial cells, and downregulation of its expression in MCF-10A cells 
prevents the occurrence of anoikis (151, 152).  Interestingly, in MCF-10A cells 
upregulation of Bim expression after loss of anchorage requires the activity of the 
MAPK/ERK pathway, but not of PIK3/AKT (151).  In contrast, we found that in 
HCT116+Chr3 maintained in suspension, upregulation of Bim expression is independent 
of both MAPK/ERK and PIK3/AKT activities, since use of the pharmacological 
inhibitors U0126 or LY294002 did not effect Bim expression.   
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Finally, Bcl-2 is aberrantly overexpressed in a number of human cancers, and the 
overexpression of Bcl-2 has been shown to promote resistance against apoptosis induced 
by different stimuli, including the lack of attachment (145).  Bcl-2’s survival function is 
neutralized by its interaction with BH3-only proteins like Bim, and by post-
transcriptional modifications (153).  Our results indicate that the TGF-β-induced increase 
in Bcl-2 expression observed in HCT116+Chr3 may be due in part to the downregulation 
of Bim expression, but also to regulation of Bcl-2 phosphorylation in Serine 70, which 
also determines its survival function (NMM and WMG unpublished data).  Thus, these 
results suggest that protein kinases that have been associated with Bcl-2 phosphorylation 
such as JNK or PKC, may play a role in TGF-β-mediated protection against anoikis. 
Thus, we provide evidence of the molecular mechanisms through which cell-autonomous 
TGF-β signaling is able to promote colon cancer progression.  Furthermore, our studies 
highlight the relevance of the cellular context in the determination of the cell responses to 
TGF-β stimulation.  Hence, if the TGF-β signaling pathway is to be considered for 
potential therapeutic strategies, it will be crucial to evaluate the oncogenic background of 
each neoplasm in order to determine the impact of inhibiting a pathway that can be both 
tumor inhibitor and tumor promoter. 
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Colorectal cancer is a pathological condition that results from the successive 
accumulation of genetic and epigenetic alterations in normal colonic mucosa.  This type 
of cancer is the third most common cancer in both men and women in the United States, 
and the second most common cause of cancer-related death (1).  The high incidence of 
this condition in the population of the developed world, in addition to the modest 
improvement in the 5-year relative survival rate of patients diagnosed with advanced 
stages of this disease in the last twenty years, demand a comprehensive investigation of 
the molecular basis of this type of cancer in order to identify potential targets for 
therapeutic intervention.  Moreover, the growing appreciation of the complexity of the 
effects that altered oncogenes and tumor suppressor genes have on the behavior of cancer 
cells also creates the need to study these effects in a context that is relevant to the primary 
cancer under investigation.  Thus, the studies described here were aimed at achieving a 
better understanding of the role of TGF-β signaling in intestinal cancer development 
through the use of in vivo and in vitro model systems in which deregulated TGF-β 
signaling could be studied in the context of distinct signaling network deregulation 
patterns.  These approaches allowed us to investigate different aspects of this signaling 
pathway and their impact on the process of intestinal carcinogenesis.   
We first generated a novel mouse model in which TGF-β signaling is impaired in the 
epithelial compartment of both small and large intestines.  Using Cre-LoxP technology 
we designed the Tgfbr2IEKO mouse model in which Tgfbr2 is deleted exclusively in the 
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epithelial cells of the intestine.  It is important to highlight that the Tgfbr2IEKO mice 
closely replicates a genetic alteration frequently found in at least one fourth of advanced 
sporadic human colorectal cancers, i.e. inactivating mutations of TGFBR2 (35), and it 
presents several advantages over other approaches that have been used to block or 
attenuate TGF-β signaling in vivo.  The TGF-β type II receptor is a required component 
of the heteromeric TGF-β receptor complex, and it is a unit for which no surrogates have 
been found so far (131); therefore, targeting this gene for deletion ensures complete 
blockade of all TGF-β-induced cellular responses.  This approach to achieve TGF-β 
signaling inactivation differs from those based on the deletion of TGF-β’s downstream 
effectors, such as Smad2, Smad3 and Smad4, because the latter affect Smad-dependent 
signals but not those independent from that pathway.  Furthermore, animal models based 
on Smad4 constitutive haploinsufficiency disturb not only TGF-β signals but also those 
from BMP ligands, which have been shown to be essential for normal development of the 
intestinal epithelium (104).  Alternative strategies that have been employed to the same 
end have other significant limitations.  Constitutive deletion of Tgfb1 in immunodeficient 
animals, for instance, impairs TGF-β signaling in epithelium, stroma and immune 
compartments, all of which are involved in the development of intestinal neoplasms; and 
the use of dominant-negative TGFBR2 transgenes may affect both TGF-β- and BMP-
induced signals (128).  Consequently, the specific effects of TGF-β signaling inactivation 
in tumor cells in such animal models are not clear.  Therefore, the Tgfbr2IEKO mouse 
model is an innovative and important tool for evaluating the specific effects of TGF-β 
signaling pathway inactivation on intestinal biology and pathologies such as 
carcinogenesis. 
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Our studies with the Tgfbr2IEKO mouse model show that deletion of Tgfbr2 in the 
epithelial cells of small intestine and colon does not appreciably alter the homeostasis of 
these tissues.  Accordingly, Tgfbr2IEKO mice do not display changes in normal intestinal 
epithelial cell proliferation in comparison to Tgfbr2E2flx/E2flx mice, and the intestinal tissue 
architecture of these two genotypical groups is identical.  Additionally, we found that 
abrogation of TGF-β signaling in this cellular compartment does not promote the 
development of spontaneous tumors even in elderly animals.  These findings challenge 
the significance of a multitude of reports based on in vitro studies that stress the 
importance of the cytostatic effect of TGF-β on most epithelial cells (78).  Our results 
also suggest that there are mechanisms that compensate for the lack of TGF-β activity in 
in vivo circumstances.  Accordingly, at least in the absence of tumor-initiating alterations, 
Activin-induced activation of Smad2/3 and other non-Smad pathways may be a part of 
the mechanism that compensates for the deficiency of TGF-β signaling in intestinal 
epithelial cells in vivo.  Thus, in the context of an intact signaling network, loss of TGF-β 
mediated signaling in the intestinal epithelium can be accommodated and the tissue can 
maintain its normal histological state and gross function.   
The Tgfbr2IEKO mouse model also allowed us to evaluate the effect of inactivating TGF-β 
signaling in epithelial cells in which the Wnt/β-catenin pathway is aberrantly activated, a 
situation that recapitulates a set of conditions commonly observed in human intestinal 
tumors.  Thus, the Apc1638N/wt; Tgfbr2IEKO mouse demonstrated that the inactivation of 
TGF-β signaling in the background of oncogenic activation of the Wnt/β-catenin 
pathway dramatically promotes intestinal tumor progression.  The synergistic cooperation 
between these two genetic alterations is reflected in a highly significant increment in the 
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number of adenocarcinomas in the Apc1638N/wt; Tgfbr2IEKO animals compared to the 
Apc1638N/wt; Tgfbr2E2flx/E2flx control group.  Importantly, the progression from benign 
lesions to invasive adenocarcinomas in these animals does not seem to be due to the lack 
of the growth inhibitory effect of TGF-β over epithelial tumor cells, because we found 
that cell proliferation in tumors with or without Tgfbr2 is not statistically different, 
similarly to what we found in the normal intestinal mucosa of these mice.  We 
established, nevertheless, that TGF-β directly regulates the expression and activity of 
MMP-2 and MMP-9 in tumor epithelial cells, which we predict is associated with the 
increased invasiveness of tumors that lack Tgfbr2.  These results suggest that primary 
effects of TGF-β signaling inactivation in Apc-initiated neoplasms are deregulation of 
host-tumor interactions and extracellular matrix remodeling, and not cytostasis of tumor 
epithelial cells.  
Matrix metalloproteinases are the principal ECM-degrading enzymes.  During the 
formation of tumor metastasis, the proteolytic activities of these enzymes are required for 
the process of ECM-remodeling associated with tumor cell invasion of the stroma, intra- 
and extravasation into and from the circulatory system, respectively (154).  Several 
studies have reported increased protein expression and activity of MMP-2 and MMP-9 in 
tumor tissue from colon cancer patients in comparison to their normal colonic mucosa 
(reviewed in (154)).  Moreover, some of such studies have indicated that there is a 
positive correlation between the expression of these proteases and the Dukes’ tumor stage 
(155, 156).  These findings reinforce the concept that the activities of MMP-2 and MMP-
9 are required for tumor invasion and metastasis, which according to our studies, are at 
least partially regulated by TGF-β signals conveyed to tumor epithelial cancer cells.   
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Previous studies have indicated that TGF-β controls the expression of MMP-2 and MMP-
9 in a cell type-dependent fashion.  It has been shown that TGF-β stimulation to different 
types of cancer cells induces the expression and activity of one or both of these two 
enzymes, and that their expression is associated with increased capacity of the tumor cells 
to migrate and invade in in vitro assays (157, 158).  Conversely, it has been established 
that TGF-β can also have a negative impact on MMP activity by promoting the 
expression of tissue-specific inhibitors of these enzymes in certain cell types.  
Accordingly, TGF-β treatment of fibrosarcoma cells induces the expression of Tissue 
Inhibitor of Metalloproteinase-1 or TIMP-1, which impairs the ability of these cells to 
invade in in vitro conditions (159).  
Through our animal model we were also able to establish that tumor tissues derived from 
Apc1638N/wt; Tgfbr2IEKO animals contain higher amounts of TGF-β1, which are likely 
related to the intense stromal component and mucinous cysts observed in these tumors.  
Furthermore, the analyses we carried out with tumor-derived epithelial cells in vitro 
suggest that reduced consumption of TGF-β1 by Apc1638N/1638N;Tgfbr2IEKO cells may be 
an important contributor to the overall increase in the amount of this cytokine found in 
the tumors.  It has been established that TGF-β stimulation promotes proliferation and 
activation of tumor-associated fibroblasts (82).  Furthermore, high levels of TGF-β1 in 
the tumor microenvironment have also been associated with defective immune responses 
against tumor cells and with increased formation of blood vessels (52, 68).  These 
observations highlight the significance of paracrine TGF-β signaling as mediator of the 
interactions between tumor epithelial cells and the stromal and immune components of 
the tumor.  Additionally, since the Apc1638N/wt; Tgfbr2IEKO mice is a conditional knockout 
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model, it facilitates a more accurate analysis of TGF-β-mediated interactions between 
epithelial and stromal tumor cells that are critical for tumor progression. 
In aggregate, our data indicate that TGF-β signals conveyed to intestinal epithelial cells 
with abnormally activated Wnt/β-catenin pathway potently suppresses tumor progression, 
and that this is not entirely caused by TGF-β’s growth inhibitory effect, but very likely by 
TGF-β-regulated host-tumor interactions and extracellular matrix remodeling.  
In marked contrast, the in vitro studies we carried out with human colorectal cancer cell 
lines indicate that TGF-β signals can exert a pro-tumorigenic effect by protecting cancer 
cells from apoptosis triggered by inadequate cell-cell or cell-matrix interactions.  Thus, 
we were able to establish that TGF-β stimulation in the context of MAPK/ERK and/or 
PIK3/AKT activation induces resistance against anoikis in a subset of human colorectal 
cancer cell lines, and this is also associated with modulation of the expression of Bcl-2 
family members.  These results provide plausible mechanisms to explain conflicting data 
from different epidemiological studies that have suggested that maintenance of an intact 
TGF-β pathway in tumor cells has pro-tumorigenic effects in colorectal cancer(38, 39), as 
our data indicate that these conflicting results may reflect the context dependence of the 
effects of TGF-β signaling inactivation on the behavior of colorectal cancer cells. 
Through the use of both in vivo and in vitro model systems, the studies described here 
enhance our understanding of the role of TGF-β signaling in the process of intestinal 
carcinogenesis.  Our data show that in this type of malignancy TGF-β signals 
paradoxically contribute to both tumor suppression and tumor promotion by virtue of 
their effects on tumor epithelial and stromal cells (figure 4-1).  Moreover, they reiterate 
that the ultimate effect of TGF-β signals, or the lack of them, is determined after the 
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Figure 4-1.  Model of the role of TGF-β signaling in intestinal cancer development 
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integration of multiple signals simultaneously conveyed to tumor cells.  Thus, in the 
background of deregulated signaling networks, such as abnormally activated Wnt/β-
catenin, PIK3/AKT and/or MAPK/ERK signaling pathways, TGF-β signals transmitted 
to tumor cells are modulated differently than in normal conditions, and consequently their 
effects are quite distinct from those seen in normal cells. 
The paradoxical effects of TGF-β signaling in our model systems of intestinal cancer are 
apparent in several respects.  In the murine model we found that tumor progression is 
suppressed by the expression of an intact Tgfbr2 in intestinal epithelium of Apc1638N/wt; 
Tgfbr2E2flx/E2flx mice.  In this case, we determined that the ability of TGF-β to inhibit 
tumor progression is probably related to a cell-autonomous function of this cytokine, i.e. 
TGF-β’s ability to downregulate the expression and activity of matrix metalloproteinases 
in tumor epithelial cells.  However, the human colorectal cancer model systems we 
studied showed that TGF-β stimulation to the cell lines HCT116+Chr3 and CBS 
maintained in vitro confers on them resistance to anoikis and, presumably, it enhances 
their metastatic potential.  These results suggest that through another cell–autonomous 
mechanism TGF-β signaling can promote cellular behaviors associated with tumor 
progression.  On the other hand, we established that intestinal tumors from Apc1638N/wt; 
Tgfbr2IEKO mice contain high amounts of TGF-β1 that, as described previously, alters 
host-tumor interaction favoring tumor progression.  Thus, TGF-β signaling on stromal 
cells may promote tumor progression in the Apc1638N/wt;Tgfbr2IEKO animal model through 
cell-nonautonomous mechanisms.  These conflicting effects, that illustrate various cell-
autonomous and -nonautonomous functions of TGF-β, underscore the relevance of the 
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cellular context and state on the definition of the net effect of TGF-β signals on tumor 
development.   
An interesting point that our results raise is the observation that in tumors from the  
Apc1638N/wt; Tgfbr2E2flx/E2flx mice, in which Tgfbr2 is not deleted and that presumably 
maintain active TGF-β signaling, TGF-β signals do not seem to exert tumor promoting 
functions as we anticipated from the data obtained from our human colorectal cancer 
systems.  According to that, we expected that advanced tumors derived from epithelial 
cells responsive to TGF-β would progress to metastatic cancer more frequently than those 
that are not responsive.  Our analysis from the ATT cell line described in chapter 2 
demonstrate that these tumor-derived epithelial cells do not undergo spontaneous 
mutations that would inactivate TGF-β signaling, although this pathway might have been 
attenuated to a certain extent considering the modest induction of the p3TPlux reporter 
activity.  Therefore, if these cells are representative of the tumors of this genotype, 
epithelial cells from these neoplasms do not acquire the oncogenic background that 
allows TGF-β signaling to act as a tumor promoting factor.  Indeed, given that TGF-β-
induced resistance against anoikis in human colorectal cancer cells is associated with 
aberrant activation of the PIK3/AKT and/or MAPK/ERK pathways, we evaluated AKT 
and ERK1/2 activation in the ATT line with and without TGF-β1 stimulation.  The 
results of this assay indicated no TGF-β-induced activity of these pathways (not shown).  
Therefore, we propose that in the absence of cross-talk between TGF-β and these two 
signaling pathways, tumors from Apc1638N/wt; Tgfbr2E2flx/E2flx do not progress to metastatic 
cancer.  Future research with genetically engineered mice with activated PIK3/AKT 
and/or MAPK/ERK pathways, for instance, and bred to the Apc1638N/wt; Tgfbr2E2flx/E2flx 
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and Apc1638N/wt; Tgfbr2IEKO mice could provide additional insight into this proposed 
model.  Alternatively, it is also plausible that in in vivo settings, TGF-β’s oncogenic 
effects are predominantly through its influence on host-tumor interactions, as observed in 
the Apc1638N/wt; Tgfbr2IEKO model, and through tumor promoting cell-autonomous 
functions like protection against anoikis are rather infrequent. 
Inactivating mutations of TGFBR2 and SMAD4 are frequently found in colon cancer (35), 
and they might be biologically equivalent.  However, since TGF-β signaling can 
influence Smad-independent signaling cascades, it would be valuable to determine the 
difference between abrogating all TGF-β-mediated cellular responses and inactivating 
only those mediated by the canonical Smad pathway.  Thus, generation of a Smad4 
intestinal conditional knockout model by crossing Smad4co/co mice (160), for example, 
with Apc1638N/wt;Villin-Cre animals should facilitate the analysis of the biological 
differences between inactivating Tgfbr2 or Smad4 in the background of Wnt/β-catenin 
activation.  The results of such studies may have some therapeutic relevance for the 
treatment of the two kinds of neoplasms.  
TGF-β signaling certainly has an important role in the development of most human solid 
tumors, and as such it has been considered as a very suitable therapeutic target.  
However, in view of the dual nature of this cytokine the decision to enhance or to repress 
TGF-β signals in order to prevent or treat tumor development in patients depends on the 
characteristics of each specific case.  For early stage tumors it could be possible to 
attempt restoring or enhancing TGF-β signals so as to intensify the growth inhibitory 
effects of this cytokine.  Hence, in cases in which the defect in the pathway is due to 
reduced receptor expression or activation of other oncogenes, the use of small molecules 
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may be beneficial.  In vitro analyses have shown that treatment with the histone 
deacetylase inhibitor MS-275 inhibits proliferation of breast cancer cells refractory to 
TGF-β-induced growth arrest, and that its effect is associated with a significant increase 
in TGFBR2 expression (161).  Similarly, it has been demonstrated that Captopril, an 
angiotensin-converting enzyme inhibitor, and FTI-277, a farnesyltransferase inhibitor, 
promote the expression of TGFBR2 in renal and pancreatic cancer cells, respectively.  
Thus, these reports suggest that increasing TGFBR2 expression in cancer cells with an 
attenuated but functional TGF-β pathway sensitizes them to the growth inhibitory signals 
of this cytokine (162, 163). 
In contrast, in instances in which excess of TGF-β signaling has tumor-promoting effects, 
like in advanced or metastatic disease, it would be desirable to inhibit the activity of this 
pathway.  To this end, several strategies are under development and include natural and 
synthetic inhibitors of TGF-β (decorin and the antisense oligonucleotide AP-12009); 
TGF-β neutralizing antibodies (Lerdelimumab, Metelimumab, and GC-1008); soluble 
forms of TGFBR2 and TGFBR3 (SR2F and Betaglycan); and TGFBR1 kinase inhibitors 
(LY550410, SB-505124 and SD-208) (reviewed in (164)).  All these approaches have 
promising therapeutic potential given the magnitude of all the tumor promoting activities 
of TGF-β signaling; however, their use in colorectal cancer has to be carefully evaluated 
in light of the results of our animal model and those from Wu and collaborators (165).  
Their work shows that abrogation of TGF-β1 and TGF-β2 expression in the weakly 
tumorigenic human colon cancer cell line CBS dramatically elevates tumor growth in a 
xenograft model.  Thus, the data collected from these two in vivo models strongly suggest 
that blockade of TGF-β signaling to treat intestinal tumors that exploit the pro-
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tumorigenic program of TGF-β signals would potentially promote the progression of 
other tumors at earlier phases of development in which TGF-β signaling is predominantly 
a tumor suppressing pathway.   
In summary, in order to design effective cancer therapies that target the TGF-β signaling 
pathway, it is crucial to identify the factors that determine the balance between the 
opposing properties of TGF-β signals such us the ones described in this study.  Hence, in 
order to formulate personalized therapies based on the manipulation of TGF-β signaling 
in tumors, it is necessary to establish the influence of other signaling cascades on TGF-β 
signals in a context-dependent fashion and also their mechanism of action.  Therapeutic 
approaches designed with such underlying principles should potentially have better 
efficacy and less toxicity than the ones that are in use currently. 
It is important then to consider therapeutic approaches based on the regulation of the 
specific signal transduction pathways that result aberrantly up- or down-regulated as 
consequence of TGF-β signaling inactivation because they could represent viable 
alternatives to the strategies based on direct manipulation of the TGF-β pathway.  
According to our findings, the expression and activity of MMP-2 and MMP-9 is up-
regulated in intestinal tumor epithelial cells that lack Tgfbr2, therefore therapeutic routes 
leading to the specific inhibition of these proteases during intestinal cancer progression 
could be beneficial, and they may also circumvent the potential deleterious effects of 
complete TGF-β signaling inactivation. 
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